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ABSTRACT 
 
Poly (DL)-lactic-co-glycolic acid (PLGA) based delivery systems have been used 
extensively for the delivery of a range of therapeutic molecules. Here, a biomimetic 
approach to organic solvent-free microencapsulation of proteins based on the self-healing 
capacity of poly PLGA microspheres is developed to overcome issues associated with 
delivery of proteins. The biomimetic approach involves incorporation of biomaterials in 
the microparticles, which would actively bind and sequester growth factors, thereby 
improving the loading and stability during encapsulation and subsequent release. To 
screen BPs, aqueous solutions of BP [high molecular weight dextran sulfate (HDS), low 
molecular weight dextran sulfate (LDS), chondroitin sulfate (CS), heparin (HP), 
hyaluronic acid (HA), chitosan (CH)] and model protein lysozyme (LYZ) were combined 
in different molar and mass ratios, at 37 °C and pH 7. LDS and HP were found to bind 
> 95% LYZ at BP:LYZ > 0.125 w/w, whereas HDS and CS bound > 80% LYZ at 
BP:LYZ of 0.25–1 and < 0.33, respectively. The BP-PLGA microspheres (20–63 μm) 
were prepared by a double water–oil–water emulsion method with a range of BP content, 
and trehalose and MgCO3 to control microclimate pH and to create percolating pores for 
protein. Biomimetic active self-encapsulation (ASE) of proteins [LYZ, vascular 
endothelial growth factor165 (VEGF) and fibroblast growth factor (FgF-20)] was 
accomplished by incubating blank BP-PLGA microspheres in low concentration protein 
solutions at ~ 24 °C, for 48 h. Pore closure was induced at 42.5 °C under mild agitation 
for 42 h. Formulation parameters of BP-PLGA microspheres and loading conditions were 
studied to optimize protein loading and subsequent release. Hyaluronic acid (HA)-PLGA 
xxiii 
 
microsphere formulations were developed with HA of 66, 357 and 1010 kDa Mw. In the 
absence of MgCO3, LYZ loading was found to increase with HA Mw and content. This 
effect on LYZ loading was dampened by the addition of MgCO3 to HA-PLGA 
microspheres. Based on poor LYZ loading (< 2 % w/w of LYZ) and undesirable release 
kinetics, HA-PLGA microspheres were determined to be not suitable for developing a 
biomimetic approach to protein encapsulation. In contrast sulfated BP-PLGA 
microspheres were capable of loading LYZ (~ 2–7% w/w), VEGF (~ 4% w/w), and FgF-
20 (~ 2% w/w) with high efficiency. Protein loading was found to be dependent on the 
loading solution concentration, with higher protein loading obtained at higher loading 
solution concentration within the range investigated. Loading also increased with content 
of sulfated BP in microspheres. Release kinetics of proteins was evaluated in-vitro with 
complete release media replacement. Rate and extent of release were found to depend 
upon volume of release (with non-sink conditions observed < 5 ml release volume for 
~ 18 mg loaded BP-PLGA microspheres), ionic strength of release media and loading 
solution concentration. HDS-PLGA formulations were identified as having ideal loading 
and release characteristics. These optimal microspheres released ~ 73–80% of the 
encapsulated LYZ over 60 days, with > 90% of protein being enzymatically active. 
Nearly 72% of immunoreactive VEGF was similarly released over 42 days, without 
significant losses in heparin binding affinity in the release medium. Using circular 
dichroism, isothermal titration calorimetry, differential scanning calorimetry, and 
intrinsic fluorescence, we compared protein-biopolymer interactions to commonly used 
polyions like phytic acid (PA) and sucrose octasulfate (SO). We explored the potential of 
using biopolymers as stabilizing agents for the development of pharmaceutical 
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formulations of proteins. The interactions were found to be enthalpically driven and BPs 
were identified for their ability to stabilize proteins.  
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CHAPTER 1 INTRODUCTION 
 
1.1 Motivation 
 
The past decade has seen an increase of protein/peptide drugs being developed as 
pharmaceutical therapies for an array of diseases such as cancers, heart ailments and 
metabolic disorders [1, 2]. Complex macromolecular protein and peptide pharmaceutical 
formulations are generally not suitable for oral administration, as protein drugs tend to 
degrade during their passage through the gastrointestinal tract (GI) and are poorly 
absorbed across the GI mucosa. Systemic delivery is associated with increased costs and 
potential side effects/toxicity due to the absence of site-specific targeting methodologies. 
Therefore great effort has been spent on developing suitable delivery methods for 
administering these drugs [3] as their efficacy is closely related to drug stability and 
delivery. In addition, sky-rocketing healthcare costs make it essential to develop 
inexpensive yet robust delivery systems, especially with the possible launch of biosimilar 
generics in the near future. Thus, a number of drug delivery systems have been developed 
since the 1980's to explore delivery of bioactive protein drugs [1, 4, 5]. Numerous 
local/regional and targeting modalities/strategies have also been used in conjugation with 
these systems to enhance delivery and efficacy.  
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Biodegradable microparticles composed of natural or synthetic polymers have emerged 
as suitable delivery systems for controlled release of proteins, peptides, growth factors, 
small molecules and chemotherapeutic agents [6-11]. Poly (lactic-co-glycolic acid) 
(PLGA)-based polymers possess highly desirable qualities such as biodegradability and 
favorable non-immunogenic characteristics, when employed to fabricate systems for drug 
delivery. PLGA has been incorporated in numerous products approved by the United 
States Food and Drug Administration, making it an attractive polymer for developing 
new delivery systems. A major drawback of the polymer is the acidic environment when 
delivering acid liable drugs, which is commonly created by the build-up of degradation 
products in PLGA [11].  However, this issue has largely been overcome by incorporation 
of poorly soluble basic additives and other pH-modifying species into the polymer. A 
number of formulation methods have been explored to improve drug stability, loading, 
release characteristics, and processing [4, 12]. 
 
Additional considerations of protein encapsulation in microparticles are protein exposure 
to the organic/aqueous interface, shear, air/liquid interface, organic solvents and high 
temperatures [13, 14].  These factors combine to make protein encapsulation one of the 
two major issues in the development of controlled-release formulations for protein drugs, 
along with instability during in vivo release [11]. Our group has developed an 
encapsulation technique 'self-healing microencapsulation', which circumvents many of 
the traditional stresses polymer-encapsulated proteins are exposed to, and offers a 
substantial stability advantage over them [15, 16]. 
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Recently our group has developed a novel active self-encapsulation method, which is 
capable of microencapsulating proteins safely with high efficiency by simple mixing of 
porous PLGA and the protein of interest [17]. In this work, we expand on the active self-
encapsulation paradigm by introducing a biomimetic approach. This would be brought 
about by incorporating biomaterials in the microparticles, which would actively bind and 
sequester growth factors, thereby improving the loading and stability during 
encapsulation and subsequent release. The bio-mimetic approach will be adopted to 
exploit the unique interactions between growth factors and biomaterial like 
glycosaminoglycans, which are known to sequester and stabilize growth factors in vivo.  
 
1.2  Age of Biologics 
 
Biologics are rapidly emerging as a major class of drug products with expected sales of 
nearly $200 billion by 2017, representing 19-20% of total market value [2]. Proteins, 
antibodies and vaccines account for a total sales of  ~ $108 billion in 2012, with 29 
blockbusters amongst their ranks [1, 2]. In addition, sky-rocketing healthcare costs make 
it essential to develop inexpensive yet robust formulations, especially with the expected 
growth of biosimilars in the near future. A number of challenges associated with 
formulation development need to be addressed for this to happen. Stability and 
aggregation of biologics in solution is one of the major challenges being faced during 
production and storage of injectable biologics [18, 19]. Aggregation causes not only loss 
of therapeutic dosage, but could also lead to hazardous immunogenic reactions [20-22].  
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1.3 Controlled Release Formulations 
 
Sustained drug levels in the blood or target tissue for 1-3 months following a single 
injection has been a much cherished aim for numerous drug companies for delivery of 
their polypeptide drugs. This long duration is not so readily attainable by non-PLGA 
systems, which do not have commercial precedence and lack the so-called “real world 
biomaterial” status. Peptide/protein modification and no-invasive strategies have 
typically been limited to weekly dosing, due to limitations associated with the half-life of 
the therapeutic agent. However, in order to accomplish 1-3 month controlled release, 
typically high total doses would have to be delivered via the polymer system. Once 
administered to the body, the polymer would react with water to bring about polymer 
erosion and degradation and subsequent release of the drug.  
 
1.3.1 Biodegradable Polymer Delivery Systems 
 
As newer molecules have been formulated for a wide variety of diseases and therapies, 
they demand different properties for optimal delivery. A very large number of natural and 
synthetic polymers have been developed over the years for the delivery of 
pharmaceutically active compounds [7, 8, 11, 23-26]. A range of biodegradable 
biopolymers has been developed to meet these challenges [6-11]. Of these, only a few 
reach the clinic and beyond in large part because of the high costs and risk associated 
with placing unproven biomaterials in pharmaceutical LAR (long acting release) 
products. In addition, others fail because of poor drug-polymer compatibility, inherent 
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polymer toxicity, immunogenicity, low drug loading and poor preclinical performance 
[5]. 
 
In spite of these obstacles, some promising clinical results have been reported. For 
example, Locetron®, a poly (ether-ester) microsphere formulation for the delivery of 
interferon α2b, had promising phase II trials [27, 28]. PhaseBio pharmaceuticals has 
reported promising clinical results for Lucemera® and Insumera®, which are based on its 
propriety elastin-like polypeptide delivery system [29]. The extensively studied 
polycaprolactone polymer has been a part of FDA-approved therapies in the past, making 
it a possible candidate for developing controlled release products [30]. Poly(d,l-lactide-
co-hydroxymethyl glycolide) (PLHMGA) microspheres have been shown to strongly 
inhibit acidic conditions compared to equivalent PLGAs [31] and have been reported to 
release stable octreotide over 60 days [32]. Copolymerization of hydrophobic polymers 
(e.g. PLGA and PLA) with hydrophilic polymers also has been accomplished to 
overcome the issue of acidic degradation [5]. A polyoxalate based polymer system has 
been shown to be biodegradable, biocompatible, and provide better cell viability as 
compared to PLGA [33]. Polyketal copolymers have been shown to deliver imatinib 
effectively, but the inflammatory response warrants further investigation [34].  
 
As it is evident, new polymers promising better therapeutic outcomes are many but the 
challenges remain the same, namely safety and efficacy. This, lead to a number of new 
biodegradable polymers to be developed over the years, but they have faced regulatory 
and clinical hurdles. Judicious and early use of cellular and animal studies need to be 
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adopted to ensure that biocompatibility issues are overcome for the timely development 
of safe and effective drug delivery systems. Another plausible factor limiting the 
alternatives to PLGA is the gap between the research work carried out developing new 
polymers and the developmental work in the pharmaceutical industry. Most new polymer 
systems are tested exclusively in preclinical studies, and rarely undergo further clinical 
research and development. These materials fall into the "valley of death", which arguably 
impedes development of new discoveries into therapies [35, 36]. Thus, in the absence of 
robust characterization and developmental work and a more straightforward regulatory 
path to close this gap, the industry usually prefers to work with very well characterized 
and polymeric biomaterials like PLGA, already used in FDA approved parenteral and 
implantable products, to avoid delays, risks and high costs associated with regulatory 
approval.   
1.4  PLGA Microsphere Systems 
 
1.4.1 Traditional Microsphere Formulations  
 
The emulsion-solvent evaporation method is the most common method of preparing 
polymer microspheres. Four types of emulsion-solvent evaporation methods: oil-in-oil 
(O/O), oil-in-water (O/W), water-in-oil in water (W/O/W), and solid in-oil in water 
(S/O/W) are widely used. The W/O/W emulsion-based encapsulation method is the 
double emulsion process and has been shown to be ideal for water soluble proteins and 
peptides [37]. The method involves dissolving the drug in an aqueous solution and the 
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polymer in an organic solution. After mixing the solutions vigorously, an emulsion is 
created. This emulsion is added to a larger volume of aqueous solution that contains an 
emulsifier ( e.g. polyvinyl alcohol). The suspension is then stirred and the organic solvent 
removed via evaporation or extraction. The microspheres are then washed, collected and 
dried [12]. 
 
Pores are an artifact of the emulsion based manufacturing process. Honeycomb or 
sponges like structures, with visible surface pores are seen in microspheres. Percolating 
pores with interconnecting networks are defined as a pore network having access to the 
polymer surface on two sides of the microsphere. These porous spaces are locations 
where water or organic solvent were present before lyophilization, preventing 
hydrophobic polymer occupation. The porosity, a measure of the total amount of empty 
space, is important because it has been shown to correlate with the amount of drug 
release during the initial release [38]. The extent of pore formation in w/o/w emulsion 
microspheres has been found to be dependent on a number of processing parameters. The 
rate of organic solvent evaporation and the polymer concentration are very important 
factors determining the porosity [12]. The composition and size of the inner aqueous 
phase was found to play a role in porosity. Additional parameters include the volume of 
the inner water phase, osmotic pressure difference between dispersed phase and 
continuous phase, ionic strength and type of emulsifier used [39].  
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1.4.2 Stability Concerns  
 
The prevalent microsphere formulation methods have a number of drawbacks, 
particularly for delivery of proteins and other bio-macromolecules [10, 40]. The major 
issues are instability during encapsulation and release [38]. Additional problems include 
effective sterilization and variability within and across the different formulations. Unlike 
small molecules, protein/macromolecules are not only sensitive to chemical 
modifications but to minute physical modifications. These physical changes include 
aggregation, denaturation, precipitation and a change in their native conformation [41].   
 
The manufacturing process, especially the encapsulation stage is known to be extremely 
harsh. The issues arise due to aforementioned organic/aqueous interface [42], shear, 
air/liquid interface, temperature change and others. As proteins consist of hydrophilic and 
hydrophobic domains, they are surface-active and end up aggregating at the various 
interfaces created during the manufacturing process [42, 43]. Any exposure to organic 
solvents is also known to bring about denaturation [44]. Methods like ultrasonification or 
mechanical shear, used to disperse the protein in the polymer phase, introduces energy 
into the system leading to localized temperature extremes and subsequent denaturation 
[45]. Traditionally, microspheres prepared with the protein in the first emulsion, face 
stability issues when they are lyophilized prior to storage. To overcome this, a number of 
cryopreservants have been used to maintain the bioactivity of the protein encapsulated 
[46]. The stability issues are reported to arise due to freezing and dehydration of the 
microsphere and the encapsulated protein. 
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When microspheres are placed in a release environment, they become hydrated with 
water uptake in the typical range of 20-100% of microsphere weight [13]. Both the 
polymer and protein are exposed to water during rehydration which leads to 
destabilization [46]. Protein molecules become more flexible and reactive, and are thus 
less stable [47]. Surprisingly at low and high moisture levels, aggregation is at minimum 
and it tends to maximize at intermediate moisture levels [48]. The aqueous pores in the 
PLGA microparticles consist of a distribution of ‘microclimates’, exposing the protein to 
unique and diverse set of environments created by the different levels of water 
penetration, polymer degradation and number of acidic moieties. In the literature, the 
microclimate differs remarkably across all formulations. Some formulations have been 
reported to possess neutral microclimate [49], while others have reported acidic 
microclimates [50-52]. Very low pH at physiological temperature is very detrimental to 
the proteins. Extremely low or high pH can lead to the protein developing a large positive 
and negative net charge respectively, leading to possible denaturation due to strong intra-
chain repulsion. In addition, acidic moieties can cleave the peptide bond and lead to 
protein hydrolysis.     
 
Model proteins like BSA and lysozyme have been reported to degrade over time in 
PLGA microparticles [38, 53]. This is crucial as some of the proteins/bio-
macromolecules are very expensive and losses due to acidic hydrolysis would seriously 
hinder development of microparticle formulations. There are also safety concerns, e.g., 
regarding the immunogenicity of protein aggregates. To overcome this issue, a number of 
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bases (such as Mg(OH)2, MgCO3, ZnCO3) have been added to the polymer solution in an 
effort to diminish these effects by increasing the pH [38]. Possible interactions between 
the PLGA and proteins, primarily during absorption have been reported, and can be 
attributed to hydrophobic interactions between the two. The extent of interaction has not 
been quantified, but is estimated to be limited to 10% of the loaded protein [13].  
    
The other causes of protein instability during release include presence of water soluble 
oligomers, chemical reactivity and chemical changes like deamidation and oxidation [54]. 
It is believed that these factors only have a smaller role in the destabilization process for 
most proteins. Thus, any strategy to improve the stability would best be focused on the 
issues previously discussed first, and thereafter focused on the residual instability issues.  
 
A major issue with commercialization of microparticle formulation is the need for 
sterilization. This is especially challenging, as it involves neutralizing all 
microorganisms, without compromising the encapsulated protein. Traditional sterilization 
techniques like heat, filtration, chemical sterilization and others are not applicable. 
Heating would damage the polymer and protein. Filtration would not be effective, as it 
cannot eliminate organisms inside the microparticle. Treatment with ethanol, ethylene 
oxide and other chemicals is not effective as they cannot sterilize all microorganisms and 
would damage the polymer matrix. This leaves radiation as the only viable option for 
sterilization. However, irradiation has been shown to cause polymer degradation, 
proportional to radiation dosage, although this loss does not preclude product 
development. Reports also indicate that irradiation causes potential aggregation and 
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difference in release profiles [55]. Irradiation of clonazepam, BSA and ovalbumin when 
encapsulated in PLGA microspheres has led to formation of free radicals [41]. Recently 
we have shown that it is possible to sterilize ASE microsphere formulations by gamma 
irradiation, allowing for bulk manufacturing of protein loaded ASE  [56]. 
 
There is considerable variability among the microparticle formulations produced by the 
different research groups. Each group has its own protocol, equipment, process, 
environment, and location, which could be responsible for the variability. 
 
1.5 Recent Advances 
 
1.5.1 Self Encapsulation by Passive Diffusion  
 
Polymers in solution can be very mobile enabling them to repair internal damages such as 
fracture or indentation. This process of intrinsic repair is called 'self-healing'. Wool and 
O'Connor [57] have proposed an eloquent theory consisting of five stages which are 1) 
surface rearrangement, 2) surface approach, 3) wetting, 4) diffusion, and 5) 
randomization. Investigations in our lab have shown that observed pore closing 
phenomenon is believed to occur in much the same manner as traditional self-healing 
systems [39]. The healing process is initiated by the changes at the edges of the cracks, 
which then approach another surface. Wetting involves formation of an interface between 
the two surfaces. This is followed by movement of polymers and intermingling. Using 
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this behavior, our group developed an encapsulation paradigm which addresses some of 
the issues with protein instability during encapsulation and sterilization [15]. This 
paradigm uses a 'self-encapsulation' method, which minimizes initial burst. It was 
hypothesized that the unknown pore closing mechanism may be a form of polymer self-
healing, in which surface entanglements, facilitated by a temperature above the Tg, 
entangled and strengthened through random motion, and further driven by an attempt to 
minimize interfacial tension, allow polymer rearrangement and pore closing to take place 
[39]. The study also demonstrated improved protein stability over a traditional emulsion-
based encapsulation technique and possibilities of incorporating additives to improve 
release characteristics. Thus, self-healing microencapsulation may hold a significant 
advantage in delivering proteins that are known to be highly unstable. 
 
1.5.2 Active Self Encapsulation 
 
Active self- encapsulation overcomes some of the loading efficiency issues associated 
with passive self-encapsulation by incorporating a protein trapping agent. The method 
relies on a) incorporation of a substance in the PLGA pores, which strongly binds the 
protein (e.g., alum absorption of vaccine antigens) [17] and b) self-healing the PLGA 
pores by raising temperature above the hydrated glass transition temperature of the 
polymer (i.e., in the vicinity of physiological temperature). The following important 
features of active self-encapsulation have been identified: a) outstanding protein stability 
during encapsulation owing to the absence of organic solvents, high shear, and other 
protein-denaturing stresses, b) the ability to encapsulate at high loading (>1 % w/w) from 
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low protein concentrations (< 1 mg/mL), c) long-term controlled release with excellent 
protein stability, and d) the ability to encapsulate without drying the protein. Alum has 
been shown to be able to effectively absorb and retain antigen from low concentration 
solutions [17]. The optimized formulations were shown to release stable antigen over 28 
days.  
 
1.6 Biomimetic Active Self Encapsulation Paradigm 
 
In this study, I propose to incorporate biopolymers (BP) in the microspheres, which 
actively bind and sequester growth factors (GFs) [58-67]. The biomimetic approach 
would presumably enhance the stability of encapsulated protein during the loading and 
subsequent release [59, 61, 66]. BPs can also potentially enhance the biological effect of 
the protein by acting as co-factors. Exploiting the unique interactions between GFs and 
glycosaminoglycans, known to sequester and stabilize growth factors in vivo; BPs are 
used as trapping agents here to  promote uptake of proteins from aqueous solution and to 
improve encapsulation efficiency. This work explores the potential and promise of the 
biomimetic approach in overcoming some of the limitations associated with stability and 
loading during encapsulation and subsequent release. Several BPs were selected for this 
purpose, namely hyaluronic acid, chondritin sulfate, heparin, chitosan and dextran 
sulfate. These BPs are members of the glycosaminoglycan (GAG) family or have similar 
structural moieties (e.g. - dextran sulfate and chitosan). 
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1.6.1 Biopolymers 
 
Angiogenic growth factors are engaged in multiple interactions in the extracellular environment 
and on the extra-cellular surface. They bind to a variety of free or immobilized proteins, 
polysaccharides, and complex lipids present in the extracellular milieu and these interactions may 
affect their stability, integrity, bioavailability and diffusion [12]. They are found in body fluids as 
circulating complexes or immobilized in the ECM and in the sub-endothelial lamina of micro-and 
macrovasculature [58]. The ECM is largely composed of complex polysaccharides, with 
glycosaminoglycans (GAGs) being one of the major classes of polysaccharides. They are known 
to bind and regulate a number of distinct proteins, including chemokines, cytokines, growth 
factors, morphogens, adhesion molecules and enzymes [58]. GAGs are linear, generally 
sulphated, negtively charged polysaccharides with molecular weights in 10-100 kDa range [58]. 
Non-sulphated GAGs include hyaluronic acid (HA), whereas the sulphated include chondriton 
sulphate (CS), dermatran sulphate (DS), kertran sulphate (KS), heparin and heparin sulphate 
(HS).                                                                                               
 
1.6.1.1 Non Sulphated Glycosaminoglycans 
 
1.6.1.1.1 Hyaluronic Acid 
 
Hyaluronic acid (HA), is a polyanionic polysaccharide that consists of N-acetyl-D-
glucosamine and β-glucoronic acid [68]. It is frequently referred to as hyaluronan 
because it exists in vivo as a polyanion and not in the protonated acid form. It is 
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distributed widely in vertebrates and is a major component of the cell coat of many 
strains of bacteria [67, 69]. 
 
HA is a unique GAG as it is neither sulfated nor bound to a core protein. In the ECM it is 
distributed as a long chain polymer (averaging 1-4 MDa) [70]. Its chemical structure was 
first elucidated by Weissman and Meyer in 1954 and has been significantly improved in 
the past decade. The unique viscoelastic nature of hyaluronan along with its 
biocompatibility and non-immunogenicity has led to its use in a number of cosmetic, 
medical, and pharmaceutical applications. 
 
A significant amount of HA is found in synovial fluid, vitreous humor, cartilage, blood 
vessels, skin and umbilical cord. In its various forms and states, it is believed to play a 
role in tissue homeostasis, embryonic/tissue development, cell signaling cues, initiation 
and progression of pathological conditions, including aberrations of angiogenesis [69-
71]. Of significant interest is its reported role in the mediation of angiogenesis via 
interaction with binding proteins and cell surface receptors, regeneration, wound healing 
and tumor invasion [68-70]. 
 
The biologic role and cellular interaction of HA is highly dependent on chain length. In 
tissues, long chain HA plays a role in maintaining a hydrated environment, regulates 
osmotic balance, acts as a shock absorber, space filler, and as a lubricant. At the same 
time, it can sequester and release growth factors and other biological signaling molecules 
[59]. Longer chains have been reported to inhibit proliferation of EC and disrupt newly-
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formed EC layers [72]. HA oligomers are believed to cluster and activate receptors 
(e.g,CD-44, RHAMM, TLR-4) effectively, leading to inflammatory cytokine release and 
activation of inflammatory cells (e.g., EC’s and smooth muscular cells) and their 
subsequent proliferation, migrations and tissue healing/remodeling [71]. Thus through 
their interaction with receptors, HA oligomers can induce neo-angiogenesis and sprout 
formation, both vital processes for tissue repair and growth.     
 
1.6.1.1.2 Sulphated Glycosaminoglycans 
 
The highly sulphated analogues, heparin and HS, have been studied extensively due to 
their well understood functions in anti-coagulation. Heparin is known to be highly 
evolutionarily conserved with similar structures found in a broad range of vertebrate and 
invertebrate organisms [63].  
 
Heparin consists of repeating units of 1→4 linked pyranosyluronic acid and 2-amino-2-
deoxyglucopyranose (glucosamine) residues [60]. The uronic acid residues typically 
consist of 90%L-idopyranosyluronic acid (L-iduronic acid) and 10%D-
glucopyranosyluronic acid (D-glucuronic acid). 
 
Various growth factors bind to the ECM of target tissues by forming tight complexes 
with sulphated-glycosaminoglycans [73]. Variations of the fine structure of the GAG 
chains may allow cells to control their responses to individual growth factors and to 
change the specificity of their response to different members of the growth factor family. 
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Reports indicate that GAG's mediate the activity of FGF-2 by inducing dimer formation 
and transient dimerization though specific interactions with FGF-2 and its receptor [74, 
75]. No significant change in the structure of FGF-2 was observed upon binding. 
Sulphated-GAG's bind to different VEGF isoforms, exerting multifaceted effects. They 
contribute to VEGF accumulation in the ECM and acts as EC core-receptors for VEGF 
[65]. 
 
The effect of GAG's on VEGF165 would depend upon the size of the chains, high 
molecular weight chains increase VEGF binding to receptors while the lower molecular 
weight chains inhibit pro-angiogenic activity of VEGF165.    
 
1.6.1.1.3 Chitosan 
 
Chitin, poly[h(1α4)-2-acetoamido-2-deoxy-D-glucopyranose], is one of the most 
abundant natural polysaccharides and is present in crustacea, insects, fungi, and yeasts. 
Deacetylation of chitin by alkali produces chitosan (CH). The molecular structure of CH 
is believed to be a copolymer of N-acetyl-glucosamine and glucosamine; usually the 
glucosamine content is more than 90% [67].                            
 
Since CH has an amino group in the repeating unit, it affords ammonium groups in 
aqueous acidic media, at neutral pH. Owing to its cationic nature, CH spontaneously 
forms water-insoluble complexes with anionic polyelectrolytes [67]. Therefore, CH has 
been used mainly as a flocculent for the treatment of wastewater. However, it has been 
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increasingly used in biomedical and pharmaceutical fields because of its favorable 
properties of good biocompatibility, low toxicity, and biodegradability. 
 
1.6.2 Protein-Glycosaminoglycans Interactions 
 
The specificity of GAG-protein interactions is governed by the ionic interactions of the 
sulfate and carboxylate groups of GAGs with the basic amino acids on the protein as well 
as the optimal structural fit of a GAG chain into the binding site of the protein. The 
topology and distribution of the basic amino acids of the GAG binding site on the protein 
influences its specificity in molecular recognition of GAG sequences [60]. The binding 
affinity of the interaction depends on the ability of the oligosaccharide sequence to 
provide optimal charge (orientation of sulfate groups) and surface (van der Waals 
contact) complimentarity with the protein, which is governed by the three-dimensional 
structure and conformation of GAGs [60]. 
  
Co-crystal structures of HS-oligosaccharides have highlighted the ionic interactions 
between specific sulfate groups and carboxylate groups of HS with the basic amino acids 
in the GAG binding site on the protein [60]. However, ionic contacts are not sufficient to 
explain the optimal structural fit of a GAG oligosaccharide to the binding site of the 
protein that influences the affinity of the interaction. From the standpoint of GAG 
conformation, it can be envisioned that protein binding would induce local distortions in 
an otherwise uniform helical structure of GAGs, which are manifested as changes in the 
glycosidic torsion angles. These conformational changes would enable an optimal 
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structural fit in terms of both ionic and van der Waals contact between the 
oligosaccharide motif and the protein.  
 
 
Figure 1-1 : Model of heparin/HS docking with VEGF165 heparin binding domain [77]. 
 
Strong ionic interactions are expected between GAGs and proteins [58]. Clusters of 
positively charged basic amino acids on proteins form ion pairs with spatially defined 
negatively charged sulphate or carboxylate groups on heparin chains. 
Glycosaminoglycans interact with residues that are prominently exposed on the surface 
of proteins. The main contribution to binding affinity comes from ionic interactions 
between the highly acidic sulphate groups and the basic side chains of arginine, lysine 
and, to a lesser extent, histidine [63]. The interactions of GAGs with proteins also involve 
a variety of different types of interactions, including van der Waals (VDW) forces, 
hydrogen bonds, and hydrophobic interactions with the carbohydrate backbone. It has 
also been observed that heparin-binding domains contain amino acids such as asparagine 
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and glutamine, which are capable of hydrogen bonding. The affinity of heparin-binding 
proteins for heparin/HS was also enhanced due to the presence of polar residues with 
smaller side chains like serine and glycine.  
1.7 Proteins 
 
1.7.1 VEGF (Vascular Endothelial Growth Factor) 
 
VEGF is one of the most well studied growth factor involved in EC migration, 
mitogenesis, sprouting and tube formation. Upregulated VEGF and VEGF receptor 
mRNA has been detected in the tips of invasive angiogenic sprouts and antibody 
blockade of VEGF significantly decreases micro-vessel growth [78]. Its alternate splice 
variants and isoforms are known to bind to receptor tyrosine kinase (VEGFR-1 and 
VEGFR-2). These isoforms differ by their amino acid length and, most importantly, their 
ability to bind cellular heparan sulfates (HS). The latter feature is critical to VEGF 
biology. Loss of heparin binding results in a substantial loss of mitogenic activity [79]. 
VEGF121 is an acidic polypeptide that does not bind heparin; VEGF165 is secreted but a 
significant fraction remains bound to the cell surface and ECM. In contrast, VEGF189 
and VEGF206 bind to heparin with greater affinity than VEGF165 and are almost 
completely sequestered in the extracellular matrix (ECM) [80]. 
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Figure 1-2 : Rendering of heparin-binding domain of VEGF165 (Protein Data Base). 
 
  
VEGFs may become available to endothelial cells by at least two different mechanisms: 
free proteins (VEGF 121 and VEGF 165) or following protease activation and cleavage 
of the longer isoforms. As a result, VEGF levels are tightly regulated and even minor 
changes can have profound physiological effects. Native VEGF is heparin binding, 
homodimeric glycoprotein of 45,000 daltons (45kDa). The properties of native VEGF ( 
i.e. VEGF found in vivo ) closely correspond to those of VEGF165 [79]. The VEGF165 
variant binds to neuropilin, is involved in capillary morphogenesis, and is required for EC 
filopodial tip directionality during angiogenesis [78]. Precise dosing of VEGF is 
essential, as it is associated with side effects like gastrointestinal toxicity, 
hypothyroidism, proteinuria, coagulation disorders, neurotoxicity, impaired wound 
healing and excessive chaotic neovascularization [74]. 
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Recombinant human vascular endothelial growth factor (rhVEGF) behaves similar to 
native VEGF in terms of its binding to heparin and its biological activity. RhVEGF is a 
homodimeric protein consisting of 165 amino acids per monomer with a molecular 
weight of 38.3 kDa and a pI of 8.5. The protein consists of 2 domains, a receptor-binding 
domain (residues 1-110) and a heparin-binding domain (residues 111-165) [81].  
 
1.7.2  FgF-20 (Fibroblast Growth Factor 20) 
 
Fibroblast growth factors (FgFs) play vital roles in angiogenesis, morphogenesis, tissue 
re modeling and carcinogenesis. The common forms are FGF-1 (acidic FGF) and FGF-2 
(basic FGF) bind to the receptor tyrosine kinases i.e FGFR-1 and FGFR-2, respectively. 
FGF-2 has been shown to enhance VEGF production and VEGF is involved in the FGF-2 
induced expression of placental growth factors, demonstrating the crosstalk between 
growth factors [82]. Also, FGF-2 has been shown to induce synthesis of collagen, 
fibronectin, and proteoglycans by EC's, demonstrating its crucial role in ECM remodeling 
[83]. FGFs mediate signals via four structurally related receptor tyrosine kinases on cell 
surfaces (FGFR-1, 2, 3 and 4) to induce numerous biological effects. One of the best-
characterized functions of FGFs is the induction of new blood vessels. In brief, formation 
and sprouting of new capillaries involves endothelial cell proliferation and cell migration, 
as well as breakdown of surrounding ECM components. Together with the vascular 
endothelial growth factor (VEGF), FGFs are the most important regulators of these 
processes. bFGF may participate in angiogenesis in two primary ways: by modulating 
endothelial cell activity and by regulating VEGF expression. 
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 FGF-20 is 211-amino-acid polypeptide with the FGF-core domain and known to be 
preferentially expressed in the substantia niagra of the brain [84]. A hydrophobic region 
was found in the FGF-core domain of FGF-20; however, no typical N-terminal signal 
sequence was found as in some other members of the FgF family. Its monomeric mass is 
23 kD but it usually exists as a non-covalent dimer in solution. FgF-20 can be potentially 
used as a therapeutic to prevent oral mucositis, a common side effect of radio or chemo 
therapy. The therapeutic effect is due to FgF-20's ability to promote epithelial and 
mesenchymal cell proliferation. It is also reported to be involved in developing 
treatments for neurodegenerative pathologies like Parkinson's disease [85]. FgF-20 has 
been reported to be notoriously unstable and difficult to work with [86, 87]. 
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Figure 1-3 : Rendering of FgF-20 structure (RCSB Protein Data Base) 
 
1.7.3 Lysozyme 
 
Lysozyme (LYZ) is a very well studied and extensively characterized enzyme, which acts 
as a guardian by attacking cell walls of bacteria. It is found in numerous body secretions, 
and is often the first line of defense against infections. We propose to use LYZ  as a 
model protein as, it is a basic highly soluble protein, and has heparin binding activity 
[88], similar to VEGF and FgF-20. LYZ and VEGF have reported pI values of 11.35 [89] 
and 8-8.5 [90] ; whereas FgF-20 has a theoretically calculated pI of 8.9 [91].   
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CHAPTER 2 Evaluating Biopolymers as Trapping Agents for Proteins 
 
2.1 Abstract 
  
 The purpose of this study was to screen glycosaminoglycan-like biopolymers (BP) for 
use in long-term controlled release formulations that deliver therapeutic growth factors. 
Aqueous solutions of BP sodium salts [high molecular weight dextran sulfate (HDS), low 
molecular weight dextran sulfate (LDS), chondroitin sulfate (CS), heparin (HP)] and 
model protein lysozyme (LYZ) were combined in different molar and mass ratios. In 
most cases, insoluble complexes were obtained instantly upon mixing aqueous solutions 
of BP and LYZ. HP and LDS exhibited a very high efficiency in LYZ binding as the BP: 
LYZ mass ratio was raised > 1. In the case of HDS and CS, LYZ binding efficiency 
reached a local maximum and fell as the BP : LYZ was increased. BP-LYZ complexes 
formed at higher BP : LYZ ratios tended to release LYZ at a faster rate over 100 h 
compared to those at lower ratios. LYZ release also varied with ionic strength, the rate 
and extent of release increased steadily with increasing ionic strength (e.g., 0 – 0.9 M 
NaCl). Comparing differences between LDS and HDS, the rate and extent of release of 
LYZ was higher for HDS across all BP : LYZ ratios and ionic strength tested. LDS-LYZ 
and HP-LYZ complexes released highly active LYZ over 100 h. Hence, we identified 
suitable BPs for developing BP-PLGA microspheres for controlled release.  
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2.2 Introduction  
 
Angiogenic growth factors are found in body fluids as circulating complexes or 
immobilized in the extra cellular matrix [1, 2]. Complex polysaccharides, like 
glycosaminoglycans (GAGs) are known to bind and regulate growth factors. GAGs are 
linear, generally sulphated, negatively charged polysaccharides with molecular weights in 
10-100 kDa range [3].  Non-sulfated GAGs include hyaluronic acid (HA), whereas the 
sulfated include chondriton sulfate (CS), dermatan sulfate (DS), ketran sulfate (KS), 
heparin (HP) and heparin sulfate. 
 
The proposed biomimetic approach involves incorporating the GAG like biopolymers 
(BPs) in PLGA microspheres, which are known to actively bind, sequester, and stabilize 
growth factors (GFs) in-vivo [2-11]. BPs can also potentially enhance the biological 
effect of the protein by acting as co-factors [2, 4, 6]. Incorporation of BPs into the pores 
of the self-healing PLGA microspheres would presumably enhance the protein loading 
efficiency as well as its stability during the encapsulation and subsequent release, by 
protein immobilization. Note that the biomimetic complexation of human growth 
hormone with Zn
2+
 in the Nutropin Depot formulation, as occurs naturally in the 
pituitary, has been used successfully to achieve excellent stability of the encapsulated 
protein during spray-congealing encapsulation and long-term release [12, 13]. Several 
BPs were selected in this work as trapping agents for biomimetic ASE, namely, 
hyaluronic acid, chondritin sulfate, heparin, chitosan and dextran sulfate.  
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Here, we screened GAG and GAG like BP’s to develop biomimetic approach for delivery 
of growth factors (GF). To develop the biomimetic self-healing strategy, we studied the 
binding of BPs (total of 6) to a model basic enzyme with positive net charge at neutral 
pH, lysozyme (LYZ). The BPs used in this study are members of the glycosaminoglycan 
(GAG) family or have similar structural moieties (e.g., dextran sulfate and chitosan).  
 
HA is a poly-anionic polysaccharide consisting of N-acetyl-D-glucosamine and β-
glucoronic acid. It is found in synovial fluid, vitreous humor, cartilage, blood vessels, 
skin, and the umbilical cord [14]. Acting as a kind of extracellular glue, it is believed to 
play a vital role in the homeostasis, tissue development, cell signaling, regeneration, 
wound healing and tumor invasion [15, 16]. Its unique viscoelastic nature along with its 
biocompatibility and non-immunogenicity has led to its use in a number of cosmetic, 
medical, and pharmaceutical applications. Among the sulfated BPs, heparin [(1→4) 
pyranosyluronic acid  2-amino-2-deoxyglucopyranose] has been widely studied due to its 
well understood role in anti-coagulation pathway [5]. Chondroitin sulfate, polysaccharide 
chain of alternating units of N-acetylgalactosamine and glucuronic acid [ β-glucuronic 
acid-(1→ 3)N-acetyl-β-galactosamine] is the most abundant GAG in the body. Found in 
the cartilage, tendon, ligament, and aorta it binds to proteins and forms proteoglycan 
aggregates [3, 11]. A number of  growth factors bind to the ECM of target tissues by 
forming tight complexes with sulfated-glycosaminoglycans [17]. Chitin, poly[h(1α4)-2-
acetoamido-2-deoxy-D-glucopyranose], is one of the most abundant natural 
polysaccharides and is present in crustaceans, insects, fungi, and yeasts. Deacetylation of 
chitin by alkali produces Chitosan (CH). The molecular structure of CH is believed to be 
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a copolymer of N-acetyl-glucosamine and glucosamine; usually the glucosamine content 
is more than 90% [11]. Dextran sulfates are derived from dextran (linear backbone of α-
linked d-glucopyranosyl repeating units) via sulfation. The long history of the safety of 
dextrans has allowed them to be used as additives to food and chemicals, and in 
pharmaceutical and cosmetics manufacturing [18]. 
 
 
 Ionic interactions are known to govern the specificity of GAG-protein interactions [2]. 
The carboxylate and sulfate groups of GAG’s interact with the basic amino acid residues 
on the protein to create optimal structural fits of biding sites. Thus, the distribution and 
topology of the basic resides dictates the specificity of interactions and location of 
binding sites on the protein [5, 8]. For strong binding affinity, oligosaccharide sequences 
on the GAG have to provide optimal charge (orientation of sulfate groups) and surface 
(van der Waals contact) [3, 5]. Typically, GAGs interact with amino acid residues that 
are prominently exposed on the surface of proteins, with the three-dimensional structure 
and conformation of GAGs playing a crucial role. Arginine, lysine and, to a lesser extent, 
histidine are involved in the ionic interactions with highly acidic sulfate groups present 
on the GAG chains [8].  
  
 
2.3 Materials and Methods  
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2.3.1 Materials 
 
High molecular weight (~ 500 kDa) dextran sulfate (HDS), low molecular weight (~15.5 
kDa) dextran sulfate (LDS), chondroitin sulfate (~ 63 kDa, shark cartilage) (CS), porcine 
heparin (~18 kDa) (HP) sodium salts were purchased from Sigma-Aldrich. Chitosan (~ 
61 kDa) was also from Sigma-Aldrich. Lysozyme (chicken egg white) and magnesium 
carbonate were also purchased from Sigma-Aldrich. Sodium hyaluronate (HA) powders 
were obtained as a gift from Lifecore Biomedical (MN, USA). All other reagents, 
common solvents, and supplies were obtained from Sigma-Aldrich, unless otherwise 
specified. 
 
2.3.2 Preparation of BP-LYZ Complexes 
 
Aqueous solutions of BPs (HDS, LDS, CS, HP, HA of ~66 kDa, and CH) and LYZ, were 
combined at a total BP + LYZ concentration of 1 mg/ml in different mass ratios (0.09, 
0.11, 0.14, 0.20, 0.33, 1, 2, 3, 5 w/w), at pH 7 and 24 °C. After 3 h of incubation, the free 
LYZ was quantified by UV spectroscopy at 282 nm and size exclusion chromatography 
(SE-HPLC), as described below. 
 
2.3.3 Quantification of LYZ  
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2.3.3.1 Size Exclusion (SE) Chromatography  
 
SE chromatography was performed using high performance liquid chromatography 
(HPLC). The mobile phase consisted of 0.1 M sodium phosphate with 0.3 M sodium 
sulfate at pH 6.7 at the rate of 0.8 ml/min and 0.4 ml/min for SE-HPLC. Samples and 
standards were injected onto TSKgel G2000SWxl (Tosoh Bioscience, USA) on HPLC 
system. Protein detection by UV was done at 214 and 282 nm. Retention times of roughly 
11 min were observed for LYZ during SE-HPLC.  
2.3.3.2  UV Spectroscopy 
 
Quantification of protein was carried out with Synergy 2 microplate reader (Biotek, 
USA) at 214 and 282 nm with appropriate standards and controls, using 96 well plates 
(Corning, USA). 
 
2.3.4 Release Kinetics of BP-LYZ Complexes 
 
LYZ and BP solutions were combined to form BP-LYZ complexes with initial w/w 
BP:LYZ ratios (0.33, 0.14, 0.11 and 0.7). The amount of bound LYZ was evaluated by 
SE-HPLC. Release kinetics of complexes in the absence of PLGA was determined in 1 
ml PBS at pH 7.4 with complete replacement of release media at 37 °C, and LYZ 
quantification via SE-HPLC. Similarly, release kinetics and complex stability in special 
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cases were analyzed in PBS + 0.3M NaCl, PBS + 0.6 M NaCl and PBS + 0.9 M NaCl at 
pH 7.4.  
 
2.3.5 LYZ Activity Assay 
 
The activity of LYZ in solution was determined by Enzchek® lysozyme assay (Life 
Technologies, USA) as per the protocol provided. As CS was found to interfere with the 
assay, activity data for CS containing formulations are not reported. 
 
2.4 Results and Discussion 
 
Biopolymers were screened for their ability to act as protein trapping agents in order to 
enhance efficiency of ASE in PLGA via the biomimetic approach. Ideal characteristics 
for such BPs include the ability to a) absorb protein from aqueous solution and ideally 
provide a synergistic effect along with the protein, b) stabilize the bound protein and 
release the bound protein when PLGA pores open, and c) not alter self-healing 
characteristics when formulated with PLGA. 
2.4.1 BP-LYZ Binding 
 
BPs were analyzed for their ability to bind to LYZ (Figure 2-1). HDS and CS binding to 
LYZ was quantified in the 0-5 (w/w BP:LYZ) range. The binding data has an optimum 
LYZ binding (~ 100 %) at HDS:LYZ of ~ 0.1 (w/w), with sharp reductions on the LYZ 
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binding on both sides of the optimum ratio. Similarly, optimum CS to LYZ (~ 100 %) 
binding was also seen at ~ 0.1 CS:LYZ ratio, with sharp declines on both sides of the 
optimum value. These sharp declines could possibly be attributed to the cross-linking 
behavior between BP and LYZ, at optimum binding ratios, which are governed by the 
charges on the interacting species, polymer size, shape, and pH of the solution, for 
example [19, 20].   
 
When HP and LDS binding to LYZ (0-5 w/w, BP:LYZ) was investigated, > 95% of the 
LYZ was bound above ~ 0.1 BP:LYZ across the range of ratios investigated. This is in 
contrast to HDS and CS, which displayed an optimum LYZ binding efficiency at a 
BP:LYZ ratio of ~ 0.1. The highest binding efficiency was observed at low ratios 
BP:LYZ, and decreased as the ratio increased. It is important to note that as compared to 
Mw of HDS and CS, LYZ has similar Mw to HP and LDS. This could potentially provide 
some hints to the difference in the binding behavior observed. 
 
HA binding to LYZ was studied over 0-50 (HA:LYZ, w/w). The binding efficiency was 
found to be the highest at the lowest mass ratios of HA:LYZ, and decreased as the ratio 
was increased to 10. The efficiency increased to ≈ 18% at around a HA:LYZ  mass ratio 
of 49. A similar trend was seen in the case of CH as the binding efficiency decreased 
from 68% to 28% at around a CS:LYZ  mass ratio of 1 and then increased to ≈ 100% as 
the ratio increased to 25. The increase in LYZ binding in case of CH around the 
minimum value of LYZ binding is much sharper when compared to the change in binding 
in case of HA. 
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Molar ratios were similar to mass ratios in the cases of LDS, HP, and HA binding to 
LYZ. HDS with average Mw of 500 kDa has a very narrow HDS:LYZ molar ratio (≈ 
0.001) for achieving ~ 100% LYZ binding. Similarly, for CS:LYZ a narrow molar ratios 
(~ 0.03) were observed for optimum LYZ binding. 
 
It is noted that HA formed gels, when combined with LYZ solutions, whereas the 
sulfated BPs formed visible precipitates. CH had very poor solubility (< 3 mg/ml) in 10 
mM phosphate buffer solution at pH 7. Thus, because of its poor solubility CH was not a 
suitable candidate for developing BP-PLGA formulations with high w/w CH content. 
 
 Thus, based on the binding data, BP-PLGA microspheres were expected to sequester 
proteins into the microspheres from the aqueous protein solution during 
microencapsulation. Based upon the binding efficiencies, LDS and HP were expected to 
perform well in BP-PLGA microspheres as they have excellent binding at BP:LYZ mass 
ratios of  > 0.13, whereas HDS and CS formulations would have to be optimized to bring 
about high loading and encapsulation efficiency of protein uptake from aqueous solution 
during ASE.  
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Figure 2-1: BP-LYZ binding profiles after 3hrs at 24°C. LYZ profiles quantified by UV at 280nm (A-C, E-F) 
and SEC-HPLC (D). The values are expressed as mean ± SD, n=3. Mass (─○─) and Molar Ratios (─●─) of 
BP:LYZ 
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2.4.2 BP-LYZ Complexes 
 
After screening for the ability to bind LYZ, the next step was to check the stability of 
sulfated BP-LYZ complexes and evaluate the release kinetics of the bound LYZ. Ideally, 
BP-LYZ complexes would be able to release all of the bound protein in an active form 
and with suitable release kinetics.    
 
 
2.4.2.1 Release Kinetics of BP-LYZ Complexes 
 
BP:LYZ complexes were formed by combining BP and LYZ solutions at different mass 
ratios. The complexes were incubated in PBS, at pH 7.4 and 37 °C. Release kinetics was 
evaluated with complete release media replacement and quantified by SE-HPLC (Figure 
2-2).  
 
 This was done to determine if the initial ratio of BP:LYZ could govern the stability and 
release kinetics of LYZ. It was important to study this ratio as it could provide some 
insight into the possible behavior to be expected when biomimetic self-encapsulation of 
BP-PLGA microspheres with a range of % BP (w/w), would be brought about at different 
protein concentrations.   
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2.4.2.2 Effect of Initial BP:LYZ on Release Kinetics 
The extent of LYZ released across complexes of a given BP formed at different BP:LYZ, 
were found to be similar after 100 h in 1ml of PBS (pH 7.4), at 37 °C (Figure 2-2). HDS-
LYZ complexes were seen to release ~ 20-40 % over 40 h and the difference in extent of 
release disappeard at 100 h, as all complexes were seen to release ~ 60 % of the bound 
LYZ. Similar differences were seen also across LDS-LYZ complexes over the first 40 h, 
when ~ 25-60 % of the bound LYZ. Over 100 h, LDS complexes released ~ 75-80 % of 
the bound LYZ. The difference in LYZ release extent was more pronounced in LDS-LYZ 
complexes formed at different initial mass ratios, when compared to HDS-LYZ 
complexes. HDS-LYZ complexes were also seen to have a smaller burst release when 
compared to LDS-LYZ. LDS-LYZ and HDS-LYZ complexes formed at a BP:LYZ ratio 
of 0.07 had significantly faster rate and extent of release compared to complexes formed 
at higher ratios. Generally, LDS-LYZ complexes were seen to release LYZ at a faster 
rate, when compared to HDS-LYZ complexes, over 100 h. 
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Figure 2:  LYZ release profiles in 1ml PBS (pH 7.4) at 37 °C from BP-LYZ complexes formed at BP:LYZ 
of 0.33 (-●-), 0.14 (-○-), 0.11 ( -▼-) and 0.07 (-∆-) quantified by SE-HPLC at 282 nm. The values are exp 
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CS-LYZ complexes were found to have comparatively similar LYZ release kinetics over 
100 h. Complexes were seen to release ~ 50-60 % over 40 h, which increased to ~ 78-90 
% LYZ released over 100 h. HP-LYZ complexes released ~ 30-65 % over 40 h and 
ultimately ~ 60-83 % of the bound LYZ over 100h. HP-LYZ complexes formed at lower 
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Figure 2-2: :  LYZ release profiles in 1ml PBS (pH 7.4) at 37 °C from BP-LYZ complexes formed at BP:LYZ of 0.33 (-
●-), 0.14 (-○-), 0.11 ( -▼-) and 0.07 (-∆-) quantified by SE-HPLC at 282 nm. The values are expressed as mean ± SE; 
n=3. 
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HP:LYZ ratios had faster LYZ release over 100 h when compared to the complexes 
formed at higher HP:LYZ. In addition, HP-LYZ complexes were noted to have some of 
the highest burst release across all BP-LYZ complexes. HP-LYZ complex formed at 0.07 
(HP:LYZ) released ~ 60 % of the bound LYZ within the first few hour of the release 
study. 
 
Across all BPs, complexes formed at lower BP:LYZ ratios had the highest burst release. 
Overall, HDS-LYZ complexes had the lowest rate and extent of release at ~ 55-60% over 
100 h, making them an excellent candidate for developing long-acting release 
formulations. Based on the data, it is possible that LYZ loaded HP-PLGA microspheres 
would have a higher burst release, when compared to other BPs. 
 
2.4.2.3 Effect of Ionic Strength on Release Kinetics 
 
To evaluate the stability of BP-LYZ complexes and study the role of electrostatic 
interactions on complex stability and release kinetics, the ionic strength of the release 
media was varied. In-vitro release of LYZ loaded BP-PLGA complexes was quantified in 
1ml of PBS+0.3 M NaCl, PBS+0.6 M NaCl and PBS+0.9M NaCl. Due to the 
electrostatic component of the BP-LYZ interaction, the rate and extent of LYZ released 
was expected to increase with ionic strength of the release media. This was verified, as 
the rate and extent of LYZ release was found to increase across almost all the complexes, 
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with increasing ionic strength. Complexes formed with lower BP:LYZ, were generally 
found to have the fastest release kinetics with the largest burst release. 
 
After 25 h, ~ 30-55 % of the bound LYZ was released from HDS-LYZ complexes in 
PBS+0.3M NaCl (Figure 2-3). In PBS+0.6M NaCl, ~ 35-60 % LYZ was released, 
whereas ~ 60-78 % of bound LYZ was released. Similarly, LDS-LYZ complexes were 
found to release ~ 20-50 % in PBS+0.3M NaCl, ~ 30-50 % in PBS+0.6M NaCl and ~ 50 
70 % of the bound LYZ was released in PBS+0.9M NaCl (Figure 2-4). HP-LYZ 
complexes had some of the highest burst release across all the complexes studied. Clear 
differences in extent and release kinetics of LYZ were seen for complex formed at 
HP:LYZ (w/w). Also, in case of HP-LYZ complex formed at 0.11 (w/w),  faster LYZ 
release kinetics was observed in PBS+0.6M NaCl, compared to that in PBS+0.9M NaCl 
(Figure 2-5). In addition, release kinetics of complexes formed at 0.14, 0.11, and 0.7 
(w/w) were similar in PBS+0.9M NaCl. 
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Figure 2-3: LYZ release profiles in 1ml of release media (pH 7.4) at 37 °C from HDS-LYZ complexes formed at 
BP:LYZ of 0.33 (-●-), 0.14 (-○-), 0.11 ( -▼-) and 0.07 (-∆-) quantified by UV at 282 nm. The values are expressed as 
mean ± SE; n=3. 
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Figure 2-4: LYZ release profiles in 1ml of release media (pH 7.4) at 37 °C from LDS-LYZ complexes 
formed at BP:LYZ of 0.33 (-●-), 0.14 (-○-), 0.11 ( -▼-) and 0.07 (-∆-) quantified by UV at 282 nm. The 
values are expressed as mean ± SE; n=3. 
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Figure 2-5: LYZ release profiles in 1ml of release media (pH 7.4) at 37 °C from HP-LYZ complexes 
formed at BP:LYZ of 0.33 (-●-), 0.14 (-○-), 0.11 ( -▼-) and 0.07 (-∆-) quantified by UV at 282 nm. The 
values are expressed as mean ± SE; n=3. 
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Overall, the difference in release kinetics of complexes formed at different mass ratios 
(BP:LYZ) was observed to decrease as the ionic strength of the release media increased, 
suggesting that ionic strength is playing a vital role in unraveling the complex and 
releasing the LYZ. Also, ionic strength greatly reduces the effect to of initial BP:LYZ 
(w/w) ratio in determining release kinetics of LYZ. Blanch et al have shown that LYZ 
solubility at constant ionic strength and pH is constant, and its solubility is approximately 
proportional to the initial LYZ concentration [21].  
 
2.4.2.4 Activity of Released LYZ 
 
To investigate the suitability of using BPs to sequester and bind LYZ in PLGA matrix, it 
was essential to ensure that the bound LYZ is active upon being released form LYZ. The 
activity of LYZ released form BP-LYZ complexes (Figure 2-6) formed at BP:LYZ of  
0.3 and 0.1 was investigated (Figure 2-7). 
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Figure 2-6 : LYZ release profiles in 1ml PBS (pH 7.4) at 37 °C quantified by UV at 280 nm (A-D). The 
values are expressed as mean ± SD, n=3. 0.14 BP:LYZ (─○─) and 0.3 and  BP:LYZ(─●─) 0.1. 
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Figure 2-7 : LYZ activity quantified by Enzchek® lysozyme assay. The values are expressed as mean ± 
SD, n=3. 0.14 BP:LYZ (─○─) and 0.3 and  BP:LYZ(─●─) 0.1. 
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2-5). In contrast, the CS and HP complexes formed at different mass ratios had similar 
LYZ release kinetics over 100 h. Activity data for CS-LYZ are not reported as the CS in 
release media was found to interfere with the LYZ activity used. 
 
HDS-LYZ complexes were seen to release ~ 65 % of the bound LYZ. The activity of the 
released LYZ was quantified. The LYZ released from the HDS:LYZ complex formed at 
0.3 mass ratio, was found to have lower activity when compared to complex formed at 
0.1, over 100 hrs. A large amount of LYZ released from HDS-LYZ complexes formed at 
0.3 mass ratios, was noted to have poor activity during the initial release period and after 
40-100 h. In contrast, LDS complexes formed at mass ratio of 0.3 were found to have 
higher activity than the complex formed at the mass ratio of 0.1. In addition, LYZ 
released from LDS complexes were seen to have higher activity than from HDS 
complexes. It is not feasible to make further comparisons due to the errors associated 
with LYZ quantification and activity assessment. 
                         
HP-LYZ complexes were observed to release LYZ with excellent activity over 100 h. 
The overall activity of the LYZ released was much higher than that form HDS-LYZ 
complexes over 100 hrs. HP:LYZ complexes formed at 0.1 mass ratio were found to 
release highly active LYZ ( > 100 %). This could be due to poor sensitivity of the 
quantification of LYZ via UV or due to HP interference during the LYZ activity assay. 
Overall, the data suggests that LDS and HP would be good candidates for incorporating 
in PLGA matrix, as the LYZ bound to these BP's would be highly active upon subsequent 
release. 
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2.5 Conclusions 
 
The BP binding data suggests that LYZ can be very efficiently (> 90 %) bound to HDS, 
LDS and HP at suitable w/w ratios. BP-LYZ complexes prepared at different BP:LYZ 
(w/w) were evaluated to check for suitability of the release kinetics of the released LYZ. 
Role of electrostatic interactions in complex formation was ascertained by the effect of 
ionic strength on release kinetics of bound LYZ. HP-LYZ complexes were identified to 
have high burst release. LDS-LYZ and HP-LYZ complexes were found to release highly 
active LYZ (> 90 %) over 100 h.  
 
These data suggest that suitably selected BPs could potentially be incorporated in PLGA 
matrix to bind and sequester LYZ via the biomimetic approach. The feasibility of this 
approach is investigated in the following chapters. 
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CHAPTER 3 Development of Hyaluronic-PLGA Formulations 
 
3.1 Abstract 
 
Poly (DL)-lactic-co-glycolic acid (PLGA) microspheres have been widely used for 
delivery of a large number of therapeutic agents. To overcome issues with protein 
stability, a self-encapsulation paradigm based on passive loading was recently developed. 
Here we investigate an effort to improve the paradigm via a biomimetic approach to 
improve loading from dilute protein solutions using hyaluronic acid (HA). HA-PLGA 
microspheres (20–63 μm) were prepared by a double water–oil–water emulsion method 
with a range of HA content, trehalose, and MgCO3 to control microclimate pH and to 
create percolating pores for protein. Hyaluronic acid (HA)-PLGA microsphere 
formulations were developed with HA of 66, 357 and 1010 kDa Mw. Biomimetic active 
self-encapsulation (ASE) of lysozyme (LYZ) was accomplished by incubating blank HA-
PLGA microspheres in low concentration protein solutions at ~ 24 °C, for 48 h. Pore 
closure was induced at 42.5 °C under mild agitation for 42 h. In the absence of MgCO3, 
LYZ loading was found to increase with HA Mw and content. This effect on LYZ loading 
was dampened by the addition of MgCO3 to HA-PLGA microspheres. Release kinetics of 
LYZ from HA-PLGA microspheres was evaluated in 1 ml PBS at 37 °C (pH 7.4), with 
complete media replacement. No significant differences were observed in release kinetics 
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of LYZ from HA-PLGA microspheres with a range of HA Mw and content, with ~ 37 - 
48 % of encapsulated LYZ released over 28 days. Based on poor LYZ loading (< 2 % 
w/w of LYZ) and undesirable release kinetics, HA-PLGA microspheres were determined 
to be not suitable for developing a biomimetic approach to protein encapsulation. 
 
3.2 Introduction 
 
PLGA microspheres have been widely used for delivery of pharmaceutically active 
peptides, proteins and other bio-macromolecules [1-3]. A wide variety of techniques have 
been developed to overcome the major issues associated with the delivery of 
biotherapeutics using PLGA [4, 5]. These challenges include; instability caused by the 
manufacturing process, instability during encapsulation/loading of biomacromolecule and 
instability during in-vivo release [6]. A large number of operation parameters and choice 
of materials govern the size, shape, pore structure, surface morphology, encapsulation, 
and release characteristics of microspheres prepared with PLGA [7-10].  
 
A common misconception is that the release kinetics from PLGA are undesirable and do 
not provide continuous zero-order type release. On the contrary, it has been known for 
more than 30 years that, by incorporating a low molecular weight PLGA into the polymer 
matrix, a continuous release of polypeptides is observed without an induction time before 
polymer mass loss (should the polypeptide remain soluble) [11]. There are also PLGA 
products that release highly water-soluble peptides without a significant burst release 
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[12].  Another perception about PLGA is that proteins are unstable when encapsulated in 
PLGAs. This has become a more persistent issue, and one that is complicated by the 
analytical difficulties associated with analysis of proteins in the release media and in the 
polymer. The major issue with the commercial adoption of PLGA products could 
primarily be associated to issues related with the scaling up of lab-scale processes to an 
industrial level. 
 
Recently, after discovering the remarkable ability of small pores on the surface of PLGA 
to close spontaneously in water and overcome issues with large initial burst release [13], 
our group has  devised a paradigm to microencapsulate large molecules in water by self-
assembly of polymer chains to heal defects [14, 15].  It involves first preparing drug-free 
microspheres, in which a percolating pore network is created. Then, porous self-
encapsulating (SE) microspheres are placed in an aqueous solution containing the drug 
for encapsulation under mild agitation at a temperature below the hydrated polymer (Tg). 
This incubation allows the entry of the drug deep within the polymer matrix. The 
polymer is then healed by raising the temperature > Tg, which leads to closing of the 
pores at the surface of the polymer and separation of pores within the polymer matrix. 
The surface pore closure thus encapsulates the drug in the polymer for controlled release 
[16].   
 
This approach can be done either passively [15], or actively [17], e.g., by placing a 
"trapping agent" as an excipient in the  polymer matrix that traps the drug as it enters the 
polymer. The passive SE approach is limited in terms of the encapsulation efficiency. 
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However, the ASE (active self-encapsulation) strategy with Al(OH)3 adjuvant has 
achieved >97% efficiency of loading and (with 1-2% w/w antigen load) high  
immunoreactivity of the tetanus toxoid [17]. Moreover, the ASE microspheres could be 
sterilized by gamma-irradiation before successful encapsulation and release with little 
change in microsphere performance [18]. In this chapter, we discuss the feasibility of 
using hyaluronic acid (HA) to bring about ASE via the biomimetic approach in self-
encapsulating PLGA microspheres.  
 
3.3 Materials and Methods  
 
3.3.1 Materials 
 
PLGA with an inherent viscosity (i.v.)  of  0.57 dLg 
-1
 (50:50, PLGA DL LOW IV, lot # 
A11-071, lauryl ester end group, 51 kDa) was purchased from Lakeshore Biomaterials 
(Birmingham, Alabama). Sodium hyaluronate (HA) powders were obtained as a gift from 
Lifecore Biomedical (MN, USA). Lysozyme (chicken egg white) and magnesium 
carbonate were purchased from Sigma-Aldrich. All other reagents, common solvents, and 
supplies were obtained from Sigma-Aldrich, unless otherwise specified. 
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3.3.2 Preparation of HA-PLGA Microspheres 
 
Porous active self-microencapsulating (SM) microspheres with BP for protein absorption 
in the PLGA pores, MgCO3 as a pH modulator and porosigen [19], and trehalose [20] to 
similarly enhance the percolating pore structure of the microspheres, were prepared by 
double water-oil-water (W/O/W) emulsion. The first emulsion was created by 
homogenizing 1 ml of 250 mg/ml PLGA and MgCO3 in CH2Cl2 with an inner water 
phase of varying amount of BPs, at 18000 rpm for 60s over an ice bath, using the 
Tempest IQ
2
 (Virtis, USA). Two ml of 5% PVA solution was added to the resultant 
emulsion and the second emulsion was created by vortexing at 10000 rpm for 60s. The 
w/o/w emulsion was added to 100 ml of 0.5% PVA solution, and allowed to harden at 
room temperature for 3 h. Hardened microspheres (20-63 µm) were collected using 
sieves, washed with double-distilled water and immediately lyophilized. 
 
3.3.3 Scanning Electron Microscopy  
 
Scanning electron microcopy (SEM) images were obtained using a Hitachi S3200N 
scanning electron microscope (Hitachi, Japan). Briefly, lyophilized microspheres were 
fixed on double-sided adhesive carbon tape. Samples were coated with a thin layer of 
gold (~ 5 nm) under vacuum and images were taken at 10-15 kV excitation voltage. 
EDAX® software was used to obtain the final image.  
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3.3.4 Active Self Encapsulation of LYZ by HA-PLGA Microspheres 
 
ASE is a two-step process consisting of a loading phase followed by pore closure. Studies 
were carried out to determine the lowest temperature and duration at which a majority of 
surface pores closed while encapsulating the maximum amount of protein from the 
loading solution. Biomimetic ASE of protein was achieved by incubating blank HA-
PLGA microspheres in protein solution for 48 h at 24 °C. LYZ loading solutions were 
prepared in 10 mM phosphate buffer (pH 7). 
 
Pore closure was induced at 42.5 ºC under mild agitation for 42 h. These parameters were 
determined by quantifying effect of temperature and duration of pore closure on LYZ 
loading (discussed in next chapter). After pore closure, HA-PLGA microspheres were 
removed from the loading solution, washed with double-distilled water, and immediately 
lyophilized. To freeze-dry, microspheres were flash frozen in liquid nitrogen and 
lyophilized using a FreeZone 2.5 (Labconco, USA) at < 0.080 mbar and - 42 °C, for 24 h. 
SEM images were taken to check if a majority of surface pores had closed.  
 
3.3.5 Determination of loading and encapsulation efficiency 
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Loading of HA-PLGA microspheres was determined by a) protein content in loading 
solution after ASE, as described below and b) direct hydrolysis of ASE HA-PLGA 
microspheres followed by amino acid analysis (AAA), also as described below. 
Percentage w/w loading was quantified as  
                                           
                                            
   
     Percentage encapsulation efficiency was calculated 
as  
                                           
                                        
      . 
 
3.3.6 LYZ Quantification 
 
3.3.6.1 Size Exclusion (SE) Chromatography 
 
SE chromatography was performed using high performance liquid chromatography 
(HPLC) (Waters, USA). The mobile phase consisted of 0.1 M sodium phosphate with 0.3 
M sodium sulfate at pH 6.7 at the rate of 0.8 ml/min for SE-HPLC. Samples and 
standards were injected onto TSKgel G2000SWxl (Tosoh Bioscience, USA) on HPLC 
systems. Protein detection by UV was done at 214 and 282 nm. Retention times of 
roughly 11 min were obtained for LYZ during SE-HPLC. 
 
3.3.6.2 Amino Acid Analysis 
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Amino Acid Analysis (AAA) was performed to determine the total content of LYZ 
loaded in HA-PLGA microspheres (~ 5 mg), soluble protein solutions and standards were 
weighed into clear glass ampules in a total volume of 1.5 ml 6 N HC1. Ampules were 
sealed under light vacuum, and incubated at 110 °C for 24 h. Following incubation, each 
vial was completely emptied into microcentrifuge tubes, and the solution was evaporated 
under vacuum at room temperature. One ml of 1.0 M sodium bicarbonate buffer (pH 9.5) 
was added to each tube to neutralize the remaining acid. For individual amino acid 
analysis, a weighed amount of 350 µl of hydrolyzed protein solution and 350 µl of o-
phthaldialdehyde reagent solution were mixed and immediately injected onto a C18 
(Waters, USA) column fitted with a guard column [21, 22]. Each sample had a run time 
of 50 min, with a mobile phase at 1.4 ml/min of A) methanol-water (65:35) and B) 
methanol-THF-50 mM phosphoric acid (titrated to pH 7.5 with 10 N NaOH (20:20:960). 
The run started with 40% A for 0.5 min, 17 min gradient to 50% A, 15 min gradient to 
100% A, a 5 min isocratic elution with 100% A, 7.5 min linear gradient to 40% A, and 
isocratic 40% A for 5 min. The fluorescence (excitation at 350 nm; emission at 455 nm) 
detection was used for quantification. Protein and standards were quantified using the 
average of the 3 individual amino acids alanine, phenylalanine, and lysine [15]. 
 
3.3.7 Evaluating Release Kinetics 
 
The release kinetics of LYZ was determined by incubating LYZ loaded HA-PLGA 
microspheres at 37 ºC in the specified volume of PBS or PBST (PBS with 0.02% Tween 
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80) with complete replacement of release media. The amount of protein released was 
assayed by size-exclusion (SE) chromatography, as described above.  
 
 
3.4 Results and Discussion 
 
In the following sections, the development of HA-PLGA microsphere formulation is 
discussed. Factors governing biomimetic active self-encapsulation of LYZ and the 
subsequent release of the encapsulated LYZ were investigated.   
 
3.4.1 Development of HA-PLGA Microsphere Formulations 
 
Excipients were included in the organic/water phase to control pore structure and 
emulsion parameters in order to obtain a percolating pore network. The percolating pore 
network is required for allowing the biomacromolecule in the loading solution to enter 
deep within the microsphere during ASE, and diffuse out during subsequent controlled 
release. On the other hand, the pores should not be too large as they could lead to 
incomplete self-healing and/or poor loading efficiency, and high burst release. Polyvinyl 
alcohol (PVA) was used as surfactant, and its role was to stabilize the emulsions and 
allow for dispersion of one phase into another immiscible phase [8]. A good emulsion 
avoids coalescence and agglomeration, leading to small and regular sized microspheres 
with a small size distribution.   
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Increasing concentration or Mw of PLGA increases the viscosity of the continuous phase. 
The viscosity of the continuous phase is known to be exponentially related to the size of 
the microspheres obtained from the emulsion [23]. Higher PLGA Mw and concentration 
is also known to improve encapsulation efficiency and size of microspheres, but is also 
associated with slower drug release [24]. The quantity of the dispersed phase (or inner 
water phase) is known to be associated with irregular microsphere pore structure and 
poor drug encapsulation [25]. Use of higher agitation rate is known to create emulsions 
which yield smaller microspheres with a small size distribution [26]. Porosigens are also 
used to produce pores within the microspheres; which increase the rate of polymer 
degradation and subsequent drug release.  
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Table 3-1 : Representative list of formulation variables explored for obtaining well-formed HA-PLGA 
microspheres
1
. 
                                                 
1
 Microspheres were prepared with w/o/w double emulsion system with 1 ml of continuous phase. Two ml 
of 5 % PVA solution was added to the first emulation obtained from inner phase and continuous phase to 
obtain the second emulsion. 
 
PLGA 
 
(mg) 
 
HA 
 
Mw(kDa) %(w/w) 
 
Trehalose 
 
% (w/w) 
 
Heparin 
 
(mg) 
 
Inner 
Phase 
(µl) 
 
First Emulsion 
 
    (Rpm)   Time(s) 
 
Second Emulsion 
 
(Rpm)  Time(s) 
321.4 1010 3.4 2.2 0 400 18000 90 10000 60 
315.2 1010 6.2 0.66 0 400 18000 90 10000 60 
318.8 1010 3.8 0.73 6.5 400 18000 90 10000 60 
326.1 1010 7.1 1.1 5.2 400 18000 90 10000 60 
249.2 357 9.8 3.3 12 250 18000 120 10000 60 
251.5 357 9.5 3.3 12 250 18000 120 10000 60 
267.8 1010 8.7 3.8 0 300 18000 75 10000 60 
280.1 1010 8.8 3.8 0 300 18000 75 15000 90 
275.2 1010 10.1 1.9 6 150 15000 60 15000 90 
261.4 1010 10.7 2.0 6 150 15000 60 15000 90 
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3.4.1.1 Effect of HA Mw and content 
 
From the very beginning of the development process, viscosity of HA solutions was a 
major issue. It was crucial to ensure accurate volumes of HA solutions were being 
pipetted, especially for high Mw or high concentration HA solutions. Viscosity was 
expected to cause problems with creating good emulsions and well formed microspheres. 
Initial attempts to obtain well-formed microspheres were carried out using the high Mw 
HA (357 and 1010 kDa), as parameters developed for these could be easily applied to 
lower Mw HA formulations (Table 3-1). 
 
SEM images were used to check if microspheres obtained were well formed and had a 
visibly uniform pore structure. As anticipated, a major issue with the formulation of the 
HA-PLGA microspheres was the viscosity of the HA solution constituting the inner water 
phase. Increasing viscosity associated with higher Mw and w/w content of HA in the 
microspheres led to poorly formed primary emulsions, which in turn, led to deformed 
microspheres with non-uniform pore structure (Figure 3-1). In some cases, very viscous 
inner water phase solutions with HA led to poor/unstable primary emulsions. In other 
cases, we failed to obtain well-formed microspheres. More work would be needed to 
understand the role played by viscosity of inner phase and its effect on the quality of 
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emulsions, and subsequent microsphere formation, if microspheres with high Mw and/or 
content of HA are desired.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 : Representative SEM images of HA-PLGA microspheres. Top (left to right): Failed batch of 
micropsheres due to poor quality of emulsion, and poorly-formed HA-PLGA micropsheres (4 % 1010 
kDA). Middle (left to right): HA-PLGA micropsheres non-uniform surface pore (10 % 357  kDA). 
Bottom : Well formed HA-PLGA micropshere. 
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Upon analyzing SEM images of the microspheres of a wide variety of formulations, it 
was decided to use 250 mg/ml PLGA and 200 µl of inner phase volume for formulating 
ASE HA-PLGA microspheres. First and second emulsions were obtained at 18,000 rpm 
for 60 sec and 10,000 rpm for 60 sec, respectively. Higher speeds were used to ensure 
that small primary emulsions were created with the viscous BP containing inner water 
phase. To study the effect of Mw and % (w/w) content of HA on loading and release, 
attempts were made to obtain well formed HA microspheres with a range of Mw and HA 
content. HA of Mw of 66, 356 and 1010 kDa were used to formulate 2, 4, 8 and 13 % w/w 
HA-PLGA microspheres. We were able to obtain well-formed HA-PLGA microspheres 
with 66 kDa HA at 2 - 13 % w/w. In contrast, for 1010 and 357 kDa HA, we observed 
well-formed microspheres only for 2%, and 2 and 4 % w/w HA, respectively. 
 
3.4.1.2 Effect of Trehalose and MgCO3 
 
As noted, pore network in PLGA microspheres is usually obtained by incorporating 
simple osmotic agents like a small sugar (e.g., trehalose) or alternative porosigen (e.g., 
MgCO3). The selected excipients also act as protein stabilizers for the successful 
development of protein encapsulating biomimetic BP-PLGA microspheres.   
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To obtain stable lyophilized protein formulations, stabilizers are required to protect the 
protein during the freezing, drying and subsequent storage of the formulation [20]. 
Trehalose has been shown to be an ideal lyoprotectant, as it protects the protein during 
freezing and prevents unfolding during dehydration, due to its ability to form hydrogen 
bonds with the protein [20]. Bernstein et al. [27]  showed that when poorly soluble bases 
(e.g., MgCO3, Mg(OH)2, ZnCO3) are added to PLGAs of moderate Mw, instead of 
observing a lag phase, continuous release is observed. It is hypothesized that the base 
reacts with acids produced upon hydrolysis to form salts, which in turn, generates 
osmotic pressure and new pores for release of large molecules. Removal of acid from 
polymer phase reduces acid-catalyzed hydrolysis, slowing the PLGA degradation rate 
[28]. The inclusion of these acids induces significantly higher water uptake into the 
polymer matrix [29]. For this project, MgCO3 is used. It reacts with acidic residues in the 
polymer to form salts and/or gaseous CO2, helping to protect the encapsulated proteins 
from an acidic microenvironment. Our research group has used several poorly soluble 
bases to attenuate the microclimate pH in the polymer [28, 29]. 
 
Trehalose and MgCO3 were added to the HA-PLGA microsphere formulations 
developed, in the previous section. Formulations containing the porisigens were seen to 
have a visibly improved pore structure, as observed by SEM. We expect this 
improvement to increase protein encapsulation and lead to good continuous release 
profiles upon subsequent release.  
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3.4.2 Active Self Encapsulation of LYZ by HA-PLGA Microparticles 
 
HA-PLGA microspheres were prepared with 66 (4 and 12 % w/w), 356 (2 and 4 % w/w) 
and 1010 (2% w/w) kDa HA. These microspheres (~20 mg) were loaded in 0.5 ml of 1 
mg/ml LYZ solution and the results are reported (Table 3-2). 
 
 
3.4.2.1 Effect of HA Mw    
 
As shown in the table, active encapsulation of LYZ increased with increasing Mw. A 
similar trend was seen with increasing HA content in the HA-PLGA microspheres. 
Higher Mw HA was expected to improve LYZ loading of HA-PLGA microspheres, as the 
longer HA polymer chains were expected to be retained in the PLGA pores to a higher 
extent along with the bound LYZ. By contrast, the lower Mw HA was expected to diffuse 
out of HA-PLGA during the loading process. More work is needed to better understand 
the role of molecular chain length, viscosity, and polymer dynamics on protein binding 
and retention. 
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Table 3-2: Self-microencapsulation capacity and efficiency of optimal ASE HA-PLGA microspheres 
loaded from 0.5 ml of 1 mg/ml LYZ loading solution in 10 mM sodium phosphate (pH 7)
2
 . 
 
                                                 
2
 Theoretical content of trehalose was ~3 % w/w in the formulations. Data reported as mean ± SE, n = 7 for 
(a) SE and (b) AAA, respectively; total microsphere mass in loading solution was ~20 mg. 
 
 
HA 
        Mw    %(w/w)                                 
MgCO3 
%(w/w) 
                              LYZ Loading  
      % (w/w)
a
                     % (w/w)
b
            % Efficiency 
a
 
66 4 0 0.34 ± 0.01  0.33 ± 0.11 18  ± 1  
66 12 0 1.37 ± 0.07  1.5 ± 0.30 68  ± 2  
357 2 0 0.42 ± 0.01  0.41 ± 0.07 21 ± 0.4  
357 4 0 1.34 ± 0.01  1.33 ± 0.07 71 ± 5  
1010 2 0 1.61 ± 0.02  1.57 ± 0.21 73 ± 7  
66 4 3 0.73 ± 0.05  NA 37 ± 1  
66 12 3 0.73 ± 0.03  NA 36 ± 2  
357 2 3 0.83 ± 0.09  NA 41 ± 4  
357 4 3 0.90 ± 0.07  NA 44 ± 1  
73 
 
3.4.2.2 Effect of % w/w HA 
 
Increased HA content would provide a larger amount and surface area of HA for LYZ 
binding, which should theoretically increase the LYZ loading. In addition, the 
hygroscopicity of larger amount of HA could potentially lead to a higher uptake of 
loading solution into the microsphere. We also hypnotized that increased HA content 
would lead to larger and more viscous HA-LYZ complexes inside the microspheres, 
which would be retained for a longer time inside the microsphere, as they slowly diffuse 
out of the pores and into the release media.  
 
Such an effect of the HA content was observed, but was less pronounced than expected 
(Table 3-2). Here, it is assumed that incorporation of higher content of HA in the HA-
PLGA microsphere did not significantly alter the pore structure. 
 
3.4.2.3 Effect of MgCO3 
 
Upon the addition of 3% w/w MgCO3, the effect of varying Mw and HA content on the 
active self-encapsulation of LYZ was greatly reduced (Table 3-2). This trend could be 
due to the increased osmotic pressure created by presence of MgCO3, which could 
counteract the effect of higher Mw and HA content. In addition, the improved pore 
structure brought about by the addition of MgCO3 led to visibly larger pores on the 
1010 2 3 0.78 ± 0.06  NA 38 ± 1  
74 
 
surface of the microspheres. This could potentially lead to poor retention of the 
encapsulated LYZ inside the microspheres, as LYZ could leach out into the loading 
solution through the improved pore structure and larger surface pores. 
 
No clear trend was seen upon comparing LYZ loading of similar formulations, with and 
without MgCO3. In some cases addition of MgCO3 to formulations led to an increase in 
LYZ encapsulation (66 kDA at 4% w/w, 357 kDa at 2 % w/w) as quantified by SE, 
whereas in others a decrease was seen ( 66 kDa at 12% w/w, 357 kDa at 4% w/w). The 
difference in the loading of LYZ by AAA and SE-HPLC could be possibly due to the 
high water uptake and gel-forming nature of the HA. The uptake of the protein solution 
by the HA-PLGA microspheres could lead to a decrease in the loading solution volume 
and thus underestimate the loss of protein from solution, as measured by the SE-HPLC.  
 
3.4.3 Release Kinetics of HA-PLGA Microspheres 
 
As noted above, the size and solubility of HA-LYZ complex was hypothesized to govern 
the amount of free LYZ available to percolate through the microsphere pore structure and 
ultimately diffuse out into the release media. Higher Mw HA was expected to slow the 
release of LYZ, as LYZ bound to higher Mw HA would be expected to facilitate retention 
in the PLGA matrix. Similarly, higher w/w content of HA would also retain LYZ inside 
the microspheres for a longer time. The hypotheses were tested by evaluating the release 
kinetics of LYZ from a range of HA-PLGA microspheres with trehalose and MgCO3 in 1 
ml PBS (pH 7.4), at 37 °C. 
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3.4.3.1 Effect of HA content 
On comparing release kinetics of HA-PLGA microspheres prepared with 66 kDa, no 
significant differences were seen between formulations developed with 4% and 12% 
(w/w), as both formulations were seen to release ~ 44 % of encapsulated LYZ over 28 
days (Figure 3-2). In contrast, small difference was seen with microspheres prepared with 
357 kDa HA. HA-PLGA microspheres with 2 % (w/w HA) released ~ 48 % of the LYZ, 
whereas formulations with 4 % (w/w HA) released ~ 36 %.    
 
 
 
 
 
 
 
 
 
Figure 3-2 : LYZ release profiles in 1 ml PBS (pH 7.4) at 37 °C quantified by SE-HPLC at 282 nm. ASE 
HA-PLGA microspheres were loaded from 1 mg/ml LYZ in 10 mM phosphate buffer (pH 7). The values 
are expressed as mean ± SE; n=3; total microsphere mass in release media is ≈18 mg. 
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3.4.3.2 Effect of HA Mw 
Upon comparing, 4 % (w/w) of 66 and 357 kDa HA, the former released ~ 44 % LYZ 
while the later released ~ 38 % (Figure 3-3). In contrast both 357 and 1010 kDa HA-
PLGA formulations with 2 % HA (w/w) release ~ 46 % of the encapsulated LYZ. 
 
 
 
 
 
 
 
 
Figure 3-3 : LYZ release profiles in 1 ml PBS (pH 7.4) at 37 °C quantified by SE-HPLC at 282 nm. ASE 
HA-PLGA microspheres were loaded from 1 mg/ml LYZ in 10 mM phosphate buffer (pH 7). The values 
are expressed as mean ± SE; n=3; total microsphere mass in release media is ≈ 18 mg. 
 
Overall, all HA-PLGA formulations released ~ 37-48 % of the encapsulated LYZ over 16 
days and the release plateaued beyond that time (Figure 3-4). The plateauing of LYZ 
release beyond day 14 was noticeable across all HA-PLGA formulations. This is a major 
concern as the desired release profile is of a slow continuous release over 45-60 days. 
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3.5 Conclusions 
 
In this chapter, we determined formulation parameters for developing well-formed HA-
PLGA microspheres with 66, 357 and 1010 kDa HA. MgCO3 and trehalose were 
included as porosigens to improve protein stability and pore structure. 
   
Biomimetic self-encapsulation of LYZ was quantified by measuring loss of protein from 
loading solution and amino acid analysis. Increased LYZ loading was observed for 
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Figure 3-4 : LYZ release profiles in 1 ml PBS (pH 7.4) at 37 °C quantified by SE-HPLC at 282 nm. 
ASE HA-PLGA microspheres were loaded from 1 mg/ml LYZ in 10 mM phosphate buffer (pH 7). 
The values are expressed as mean ± SE; n=3; total microsphere mass in release mass in release media 
is ≈ 18 mg. 
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formulations with higher HA Mw and content, but this effect was greatly suppressed 
when MgCO3 was incorporated in the formulations. Release kinetics of LYZ was found 
not to alter significantly with HA Mw and content. The LYZ release was found to plateau 
around day 14 of release with a large amount of LYZ being retained inside the 
microspheres. 
 
Our data suggested that HA-PLGA microspheres are not suitable for obtaining high 
protein loading (>2% w/w of LYZ) and had poor release kinetics. Thus, we decided to 
investigate sulfated BP-PLGA microsphere formulations for biomimetic ASE, as 
discussed in the next chapter. 
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CHAPTER 4 Development of Sulfated BP-PLGA Formulations 
 
4.1 Abstract 
 
The purpose of this study was to evaluate the biomimetic active self-encapsulation of 
proteins by sulfated biopolymer (BP)-PLGA microspheres. Sulfated BPs [high molecular 
weight dextran sulfate (HDS), low molecular weight dextran sulfate (LDS), chondroitin 
sulfate (CS), heparin (HP)] were used to formulate BP-PLGA microspheres (20–63 μm). 
Microspheres were prepared by a double water–oil–water emulsion method with a range 
of BP content, trehalose, and MgCO3 to control microclimate pH and to create 
percolating pores for protein. Biomimetic active self-encapsulation (ASE) of proteins 
[LYZ, vascular endothelial growth factor165 (VEGF) and fibroblast growth factor (FgF-
20)] was accomplished by incubating blank BP-PLGA microspheres in low concentration 
protein solutions at ~ 24 °C, for 48 h. Pore closure was induced at 42.5 °C, under mild 
agitation for 42 h. Formulation parameters of BP-PLGA microspheres and loading 
conditions were optimized for protein loading. Sulfated BP-PLGA microspheres were 
capable of loading LYZ (~2-7 % w/w), VEGF (~ 4% w/w), and FgF-20 (~2% w/w) with 
high efficiency. Protein loading was found to be dependent on the loading solution 
concentration, with higher protein loading obtained at higher loading solution 
concentration within the range investigated. Loading also increased with content of 
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sulfated BP in microspheres. Release kinetics of proteins was evaluated in-vitro with 
complete release media replacement. The pH of the release media was not significantly 
affected by the presence of BPs amongst the microsphere degradation products. Rate and 
extent of release were found to depend upon volume of release (with non-sink conditions 
observed  5ml release volume for ~18mg loaded BP-PLGA microspheres), ionic 
strength of release media and loading solution concentration. HDS-PLGA formulations 
were identified as having ideal loading and release characteristics. These optimal 
microspheres released ~ 73-80 % of the encapsulated LYZ over 60 days, with > 90 % of 
protein being enzymatically active. Nearly 72% of immunoreactive VEGF was similarly 
released over 42 days, without significant losses in heparin binding affinity in the release 
medium. 
 
4.2 Introduction  
 
The ability to impart sustained drug levels in the blood or target tissue for 1-3 months 
following a single injection is a holy grail for numerous drug companies for delivery of 
their bio-macromolecular drugs. PLGA microspheres have long demonstrated an ability 
to deliver therapeutic agents from weeks to months in commercial products. This long 
duration has not being attained by non-PLGA biodegradable systems for commercial use. 
Hence, most non-PLGA based systems do not have commercial precedence and lack the 
so-called “real world biomaterial” status. 
 
83 
 
 Long-acting-release products (LARs) not only improve lifestyle by minimizing exposure 
to the needle, but also generally improve patient outcomes by improving patient 
compliance and reducing peak-and-valley blood levels [1]. The noninvasive and 
peptide/protein modification strategies have typically been limited to weekly dosing. For 
example, the ability to extend peptide and protein half-lives in blood, usually by 
modification of the peptide/protein molecule, has been accomplished by PEGylation [2], 
protein fusion (e.g., to albumin or Fc region of the antibody) [3, 4], and lipidation [5].  
  
A number of protein and peptide drugs could provide greater therapeutic benefit if the 
plasma concentration could be maintained for an extended period. In addition, other 
products could benefit from sustained delivery of systemic dose such as blood 
coagulation factors, metabolic peptides, monoclonal antibodies and antibody fragments, 
enzymes, and cytokines. Delivery of growth factors holds great promise for regenerative 
medicine for treatment of peripheral vascular and ischemic heart diseases [6-8]. 
However, systemic administration of growth factors has led to mixed clinical outcomes. 
Polymer depots can maintain systemic levels of therapeutic drug, allowing for delivery of 
drugs for local/site-specific activity. However, in order to accomplish 1-3 month 
controlled release, typically large doses have to be initially encapsulated in the polymer.  
 
In this chapter, we discuss the feasibility of our biomimetic approach to load large 
amounts of proteins efficiently, to develop LAR products using sulfated BPs. Our 
paradigm would allow us to overcome some of the major instability issues associated 
with encapsulating proteins in PLGA [9-11]. Using BPs in the PLGA matrix to bind and 
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stabilize proteins would allow proteins to be protected during loading and release, as 
upon binding and immobilization, proteins are protected from physical and chemical 
instability caused by exposure to PLGA and other destabilizing factors [11, 12]. 
 
4.3 Materials and Methods 
  
4.3.1 Materials 
 
PLGA with an inherent viscosity (i.v.)  of  0.57 dLg 
-1
 (50:50, PLGA DL LOW IV, lot # 
A11-071, lauryl ester end group, 51 kDa) was purchased from Lakeshore Biomaterials 
(Birmingham, Alabama). High molecular weight (~ 500 kDa) dextran sulfate (HDS), low 
molecular weight (~15.5 kDa) dextran sulfate (LDS), chondroitin sulfate (~ 63 kDa, 
shark cartilage) (CS), porcine heparin (~18 kDa) (HP) sodium salts were purchased from 
Sigma-Aldrich. Chitosan (~ 61 kDa) was also from Sigma-Aldrich. VEGF165 were 
obtained as a gift from Genentech. Lysozyme (chicken egg white) and magnesium 
carbonate were purchased from Sigma-Aldrich. FgF-20 was obtained from the National 
Cancer Institute-Biometric Research Branch (NCI-BRB) preclinical repository. Human 
VEGF standard ELISA development kit was purchased from Peprotech (NJ, USA). 
Cyanine-5 labelled lysozyme and FITC-dextran were bought from Nanocs (NY, USA). 
All other reagents, common solvents, and supplies were obtained from Sigma-Aldrich, 
unless otherwise specified. 
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4.3.2 Preparation of Sulfated BP-PLGA Microspheres 
 
Porous active self-microencapsulating (SM) microspheres with BP for protein absorption 
in the PLGA pores, MgCO3 as a pH modulator and porosigen [13], and trehalose [14] to 
similarly enhance the percolating pore structure of the microspheres, were prepared by 
double water-oil-water (W/O/W) emulsion. The first emulsion was created by 
homogenizing 1 ml of 250 mg/ml PLGA and MgCO3 in CH2Cl2 with an inner water 
phase of varying amount of BPs, at 18000 rpm for 60s over an ice bath, using the 
Tempest IQ
2
 (Virtis, USA). Two ml of 5% PVA solution was added to the resultant 
emulsion and the second emulsion was created by vortexing at 10000 rpm for 60s. The 
w/o/w emulsion was added to 100 ml of 0.5% PVA solution, and allowed to harden at 
room temperature for 3 h. Hardened microspheres (20-63 µm) were collected using 
sieves, washed with double-distilled water and immediately lyophilized. 
4.3.2.1 HDS(FITC)-PLGA Microspheres 
 
HDS-PLGA microspheres were prepared as described above. 
 
4.3.3 HDS-PLGA Microspheres with ZnCO3 
 
HDS-PLGA microspheres were prepared as described above, with ZnCO3 used instead of 
MgCO3. 
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4.3.4 Scanning Electron Microscopy  
 
Scanning electron microcopy (SEM) images were obtained using a Hitachi S3200N 
scanning electron microscope (Hitachi, Japan). Briefly, lyophilized microspheres were 
fixed on double-sided adhesive carbon tape. Samples were coated with a thin layer of 
gold (~ 5 nm) under vacuum and images were taken at 10-15 kV excitation voltage. 
EDAX® software was used to obtain the final image.  
 
4.3.5 Active Self Encapsulation of LYZ, FgF-20 and VEGF by BP-PLGA 
Microspheres 
 
ASE is a two-step process consisting of a loading phase followed by pore closure. Studies 
were carried out to determine the lowest temperature and duration at which a majority of 
surface pores closed while encapsulating the maximum amount of protein from the 
loading solution. Biomimetic ASE of protein was achieved by incubating blank BP-
PLGA microspheres in protein solution for 48 h at 24 °C. LYZ loading solutions were 
prepared in 10 mM phosphate buffer (pH 7) and FgF-20 loading solutions were prepared 
in 0.5 M arginine, 0.05 M sodium phosphate and 0.08% polysorbate 20 (pH 7). VEGF 
loading solutions were prepared in 5 mM succinate buffer, 275 mM trehalose and 0.01% 
polysorbate 20 (pH 5).   
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Pore closure was induced at 42.5 ºC under mild agitation for 42 h. These parameters were 
determined by quantifying effect of temperature and duration of pore closure on LYZ 
loading. After pore closure, BP-PLGA microspheres were removed from the loading 
solution, washed with double-distilled water, and immediately lyophilized. To freeze-dry, 
microspheres were flash frozen in liquid nitrogen and lyophilized using a FreeZone 2.5 
(Labconco, USA) at < 0.080 mbar and - 42 °C, for 24 h.  SEM images were taken to 
check if a majority of surface pores had closed. 
  
4.3.6 Determination of loading and encapsulation efficiency 
 
Loading of BP-PLGA microspheres was determined protein content in loading solution 
after ASE, as described in the following section. Percentage w/w loading was quantified 
as  
                                           
                                            
        Percentage encapsulation efficiency 
was calculated as  
                                           
                                        
      . 
 
4.3.7 Protein Quantification 
 
4.3.7.1 Size Exclusion (SE) Chromatography  
 
SE chromatography was performed using high performance liquid chromatography 
(HPLC) and ultra performance chromatography (UPLC) systems (Waters, USA). The 
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mobile phase consisted of 0.1 M sodium phosphate with 0.3 M sodium sulfate at pH 6.7 
at the rate of 0.8 ml/min and 0.4 ml/min for SE-HPLC and SE-UPLC, respectively. 
Samples and standards were injected onto TSKgel G2000SWxl (Tosoh Bioscience, USA) 
and Acquity BEH200 (Waters, USA) on HPLC and UPLC systems, respectively. Protein 
detection by UV was done at 214 and 282 nm. Retention times of roughly 11 and 5 min 
were obtained for LYZ during SE-HPLC and SE-UPLC, respectively. FgF-20 and VEGF 
both had retention times of roughly 5 min during SE-UPLC. The UPLC was 
preferentially used in quantifying protein release kinetics in 5 ml release media, as it had 
higher sensitivity when compared to SE-HPLC for the conditions studied. 
 
4.3.7.2 UV Spectroscopy 
 
Quantification of protein was carried out with Synergy 2 microplate reader (Biotek, 
USA) at 214 and 282 nm with appropriate standards and controls, using 96 well plates 
(Corning, USA).  
 
4.3.7.3 Coomassie Plus protein assay 
 
Quantification was carried out using appropriate standards and controls at 595 nm using 
the microplate reader, as per protocol provided by manufacturer (Coomassie Plus, 
Pierce). The assay was used to quantify VEGF loading along with SE-UPLC. 
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4.3.7.4 VEGF enzyme linked immunosorbent assay  
 
VEGF enzyme linked immunosorbent assay (ELISA) was carried out as per the 
manufacturer’s protocol. Briefly, 96 well microplates were incubated overnight with 100 
µl of 0.5 µg/ml capture antibody in PBS at room temperature. After washing with PBS 
containing 0.05% Tween 20, 100 µl of standards and samples in diluent (PBS with 0.05% 
Tween 20 and 0.1% BSA) were added in triplicate and incubated for 2 h at room 
temperature. After washing, 100 µl of 0.25µg/ml biotinylated secondary antibody in 
diluent was added to each well and allowed to incubate for 2 h at room temperature. After 
another wash, 100 µl of diluted (1:2000) avidin-HPR conjugate was incubated in each 
well for 30 min. After a final wash, 100 µl of ABTS substrate was added to each well for 
detection. Activity was determined after 25 min by monitoring plate optical density at 
405 nm with wavelength correction set at 650 nm and fitting the data using the Gen5 
software (Biotek, USA).  
 
4.3.7.5 Heparin-affinity chromatography 
 
Heparin-affinity chromatography was performed using an Alliance HPLC system 
(Waters, USA). Each sample had a run time of 15 min, with a mobile phase at 1.0 ml/min 
of A) 50 mM phosphate buffer (pH 7) and B) 50 mM phosphate buffer with 3M NaCl 
(pH 7). Samples and standards were injected onto POROS® Heparin 50 µm column 
(Applied Biosystems®, USA). The run started with 100% A for 5 min, 2 min gradient to 
0%  A, 5 min gradient to 100% A,  and an isocratic 100% A for 3 min. Heparin binding 
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VEGF was detected by UV at 214 and 282 nm with a retention time of ~ 10 min. The 
large BSA peak from the release media samples was baseline separated from the VEGF 
peak and had a retention time of ~ 3.5 min. Percentage heparin binding VEGF was 
quantified as  
                           
                          
      .  
 
4.3.8 Biomimetic ASE of LYZ(CY5) by HDS(FITC)-PLGA Microspheres 
 
Biomimetic ASE Cy5 LYZ was brought about as described above.  
4.3.9 Confocal Microscopy 
 
HDS-PLGA microspheres were prepared as described in section 2.4. The microspheres 
were loaded from Cyanine-5 (Cy5) labeled LYZ at 1 mg/ml concentration in 10 mM 
phosphate buffer (pH 7), as described above for unlabelled LYZ. After ASE, the 
microspheres were washed and lyophilized. Volumetric images of HDS-PLGA 
microspheres encapsulating Cy5-LYZ were generated by taking images at different focal 
lengths with a step size of 2 µm (Nikon A1R/A1 confocal microscope). NIS-Elements® 
software was used to combine these images into volumetric images. 
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4.3.10 Evaluating Release Kinetics 
 
The release kinetics of LYZ was determined by incubating loaded BP-PLGA 
microspheres at 37 ºC in the specified volume of PBS or PBST (PBS with 0.02% Tween 
80) with complete replacement of release media. The amount of protein released was 
assayed by size-exclusion (SE) chromatography, as described below. The activity of 
released LYZ was quantified by Enzchek®, described below. Release kinetics of VEGF 
was determined in PBST+10 mg/mL BSA, also with complete media replacement at each 
time point by ELISA, as described below.  
 
4.3.11 Measurement of pH 
 
The pH of the release media was measured by Orion model 290 pH meter (Thermo 
Scientific, USA), as per the protocol provided by the manufacturer. Measurements of 
samples were taken in triplicate.  
 
4.4 Results and Discussion 
 
In the following sections, the development of BP-PLGA microspheres is discussed. 
Parameters governing the biomimetic loading of proteins were investigated. The role of 
the type of BP, content of BP in PLGA, and concentration of loading solution on ASE of 
protein were investigated. Factors governing protein release kinetics from the BP-PLGA 
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microspheres were also investigated. The effect of BP type, BP content, volume of 
release, and ionic strength of release media on release kinetics, was studied. 
 
4.4.1 Optimization of Biomimetic ASE parameters for encapsulation of LYZ by 
BP- PLGA microspheres 
 
Biomimetic ASE is a two-step process, consisting of a loading phase followed by pore 
closure. Studies were carried out to determine the lowest temperature and duration at 
which a majority of surface pores closed, while encapsulating the maximum amount of 
protein from the loading solution. 
 
Initial attempts to determine loading temperature and duration were carried out with 
PLGA microspheres formulated with HDS, HA (66 kDa), CH (soluble chitosan) and 
blank microspheres. Pore closure should be carried out at a high enough temperature to 
ensure that the PLGA polymer chains could mobilize to allow for "self-healing" of the 
microsphere surface, but not at high enough temperature and duration to damage the 
protein. SEM images and LYZ loading was determined to check for pore closure and 
quantify loading at different time points of the pore closure study. 
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Figure 4-1 : Theoretical content of MgCO3 and trehalose was ~3 % w/w in the formulations. LYZ loading 
was quantified by SE-HPLC. Pore closure was carried out at 42.5° C. Data reported as mean ± SE, n = 3. 
 
BP-PLGA microspheres were loaded with 0.5 ml of 0.25 mg/ml LYZ in 10 mM 
phosphate buffer (pH 7) at 24 °C. Pore closure was carried out at 42.5 °C, as previously 
reported [15]. LYZ loading for the time points of study were quantified as shown (Figure 
4-1). Across all formulations studied, the highest loading was observed at 30 h of pore 
closure, but the SEM images of the microsphere surface were noted to have large surface 
pores. LYZ loading at 19 h and 50 h was also higher compared to some of time 
points.HDS and SC formulations had some of the higher LYZ loading whereas HA and 
blank microspheres consistently had some of the lowest LYZ loading during the entire 
pore closure study. The images obtained showed that a majority of the surface pores on 
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the BP-PLGA microspheres were closed beyond 42 h (data not shown). Based on these 
images, it was decided to carry out pore closure for 42 hr for all BP-PLGA microspheres.  
 
 
Figure 4-2 : Schematic of the biomimetic active self encapsulation of proteins by BP-PLGA 
 
4.4.2 Effect of BP-PLGA microspheres on release media pH 
 
To evaluate the feasibility of using BP-PLGA microspheres, we wanted to study the 
effect of BP containing PLGA formulations on the pH of the release media. This was 
brought about by carrying out a release study of unloaded HDS-PLGA, SC-PLGA, HA-
PLGA, and blank PLGA microspheres (~ 20 mg) in 1ml PBS (pH 7) at 37 °C, with 
complete media replacement. The pH profile of the release media was monitored over 28 
days (Figure 4-3).  
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Figure 4-3 : pH profile of 1ml of PBS release media (pH 7.4) with BP-PLGA microspheres (~ 20 mg) in at 
37 °C. Data reported as mean ± SE, n = 4.  
 
Across all formulations, the pH of the release media was found to drop below pH 7.4. On 
day 7 and 14, HA-PLGA microspheres were found to have the lowest pH amongst all 
formulations investigated. As expected the acidic nature of HA does bring about a 
reduction in the pH of HA-PLGA over 15 days, as compared to other formulations. At 
day 21 and 28, there were no significant differences in pH profiles, suggesting that the 
pH was primarily determined by PLGA degradation products accumulated in the release 
media and not significantly altered by any residual BP. As expected, the poor solubility 
of CH lead to SC-PLGA and PLGA formulations having similar pH profiles. It is 
important to note that no major difference in pH was seen for all other formulations 
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(including PLGA microspheres without any BP), suggesting that the pH of release media 
is not significantly affected by the addition of BP over 28 days.  
 
4.4.3 BP-PLGA Microsphere Formulations 
 
BP-PLGA microspheres were prepared with HDS, LDS, CS, and HP, based on 
parameters used for formulating optimum HA-PLGA microspheres. The viscosity of the 
inner water phase obtained using these BP's was much lower, as compared to HA. Thus, 
it was possible to produce BP-PLGA formulation with high BP (% w/w) content.  
 
To investigate the effect of BP content (% w/w) on formulations, HDS-PLGA and CS-
PLGA microspheres were produced with ~ 2, 5, and 12 % w/w. As anticipated and 
established with HA formulations, addition of larger amounts of BP in the inner water 
phase impacted the uniformity of pore structure and the morphology of the microspheres, 
as observed by SEM. In case of HDS, the microspheres did not appear to differ much as 
its content increased, but for CS formulations with 12% were noted to have non-uniform 
pore structures. 
 
4.4.4 Active Self Encapsulation of LYZ by BP-PLGA 
 
4.4.4.1 Effect of BP content 
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To study the influence of BP content in formulations on LYZ encapsulation, CS-PLGA 
and HDS-PLGA microspheres were loaded from 10 mM phosphate solutions of LYZ 
(Table 4-1 ). 
 
Table 4-1:  Biomimetic self-microencapsulation capacity and efficiency of CS-PLGA and HDS-PLGA 
microspheres
3
. 
 
 
                                                 
3
 Microspheres were loaded from 0.5 ml of 1 mg/ml LYZ solutions in 10 mM phosphate buffer (pH 
7)Theoretical content of MgCO3 and trehalose was ~3 % w/w in the formulations. Data reported as mean ± 
SE, n = 3; total microsphere mass in loading solution was ~20 mg. 
 
 
 
BP 
                            % (w/w) 
 
LYZ Loading 
       %(w/w)              % Loading Efficiency 
HDS 2 2.0 ± 0.04 
 
100.0 ± 0.8 
 HDS 5.1 2.1 ± 0.08 
 
100.0 ± 0.3 
 HDS 12.6 2.1 ± 0.02 
 
100.0 ± .9 
 CS 2 1.8 ± 0.01 
 
83 ± 0.8 
 CS 5.1 1.4 ± 0.01 68 ± 0.7 
CS 12.6 2.0 ± 0.07 93 ± 2.4 
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Across all HDS-PLGA formulations, almost all of the LYZ was encapsulated from the 
loading solution. In contrast, CS-PLGA microspheres were observed to have higher LYZ 
loading at 2 and 12 % (w/w), than at 5% CS. This suggests that even though it might be 
feasible to improve loading capacity of BP-PLGA microspheres by increasing BP 
content, there does not exist a simple linear relationship between % BP (w/w) and 
encapsulation of LYZ, in the range of formulations investigated. It is important to note 
that the formulations with high BP content had non-uniform pore structures, thus making 
them not ideal for further development. 
 
As HDS formulations had absorbed all the LYZ in the previous study, it was decided to 
load ~10 mg of HDS-PLGA (2, 5.1 and 12.6 %w/w HDS) microspheres from 1 ml of 3 
mg/ml and 0.5 ml of 6 mg/ml LYZ loading solutions (Table 4-2). A smaller amount of 
microspheres (~ 10 mg), were loaded with an excess of LYZ (3 mg), to also investigate 
the role of loading solution concentration at the same time. Loading was found to be 
higher at 6 mg/ml than at 3 mg/ml. The theoretical amount of LYZ bound to 1 mg of 
HDS increased with loading concentration. The data indicates that the maximum ASE 
capacity of HDS-PLGA microspheres increases with loading concentration of LYZ. 
Higher self-encapsulation was also seen with increasing HDS content, when loaded with 
an identical LYZ concentration. Overall, the low loading and encapsulation efficiency 
could be attributed to the HDS-PLGA having exceeded the protein binding capacity, as a 
smaller mass of microspheres was loaded with higher amount of protein.  
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Table 4-2: Self-microencapsulation capacity and efficiency of a small amount of ASE HDS-PLGA 
microspheres loaded with excess of LYZ from 10mM phosphate buffer (pH 7)
4
. 
 
 
HDS 
 
(% w/w) 
 
   Loading Solution  
 
Vol.(ml)  Conc.(mg/ml) 
 
  LYZ Encapsulation 
 
       (% w/w)  Efficiency (%) 
 
LYZ bound    
  
(mg/mg HDS) 
      
2 1 3 1.3 ± 0.1 
 
4.5 ± 0.1 
 
0.66 ± 0.01 
5.1 1 3 3.4 ± 0.4 
 
13.5 ± 0.4 
 
0.67 ± 0.03 
12.6 1 3 3.4 ± 0.3 
 
13.1 ± 0.2 
 
0.28 ± 0.02 
2 0.5 6 4.1 ± 0.01 
 
13.7 ± 0.1 
 
2.03 ± 0.04 
5.1 0.5 6 6.2 ± 0.3 
 
20.9 ± 0.5 
 
1.26 ± 0.02 
 
12.6 
 
 
 
0.5 6 8.1 ± 0.2 
 
27.1 ± 0.3 
 
0.67 ± 0.03 
 
 
 
 
 
                                                 
4
 Theoretical content of MgCO3 and trehalose was ~3 % w/w in the formulations. LYZ binding capacity 
was calculated using theoretical amount of HDS and LYZ in the loading solution. Data reported as mean ± 
SE, n = 3; total microsphere mass in loading solution was ~10 mg 
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4.4.4.2 Effect of LYZ Loading Concentration 
 
Based on the binding curves (chapter 2) and formulation issues associated with high BP 
content as discussed above, 4% w/w BP-PLGA microspheres were identified to be 
suitable for > 2 % (w/w) protein loading. Approximately 20 mg of BP-PLGA were 
loaded from 0.5, 1, and 1.5 mg/ml LYZ solutions (Table 4-3). BP-PLGA ASE 
microspheres exhibited an excellent active protein loading capabilities and efficiencies. 
LDS formulations had the lowest loading efficiencies (and corresponding LYZ loading) 
among the BPs tested. This was in contrast to the binding ratio data from chapter 2, 
which had suggested that LDS might bring about high LYZ loading across a wide range 
of LDS:LYZ ratios. HDS, CS, and HP formulations had greater than 90% efficiency 
across all loading concentrations investigated. Most of the LYZ partitioned into the BP 
containing PLGA pores when LYZ concentration in the loading solution increased from 
0.5 mg/ml to 1 mg/ml and 1.5 mg/ml (Table 4-3). This high loading capacity (~ 7 wt %) 
and efficiency (94-96%) was achieved at a lower BP:LYZ ratio in the loading solution. 
The loading was found to increase with the concentration of the loading solution in the 
range investigated; an excellent linear relationship was observed (Figure 4-4). Thus, the 
loading solution concentration could be used to obtain ASE formulations with desired 
protein content. It is important not to draw conclusions regarding the exact BP:LYZ ratio 
for high efficiency loading, as the data does not quantify the BP:LYZ in the internal pores 
of BP-PLGA microspheres.   
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Table 4-3: Self-microencapsulation capacity and efficiency of optimal ASE BP-PLGA microspheres loaded 
from 1 ml LYZ solutions in 10 mM phosphate buffer (pH 7)
 5
. 
BP 
 
Loading Solution Conc. 
(mg/ml) 
LYZ Encapsulation 
(% w/w)                    Efficiency (% ) 
HDS 0.5 2.2 ± 0.1 
 
90 ± 0.1 
 
HDS 1 4.6 ± 0.1 
 
95 ± 0.2 
 
HDS 1.5 7.0 ± 0.1 
 
97 ± 0.1 
 
LDS 0.5 1.5 ± 0.1 
 
63 ± 2 
 
LDS 1 4.1 ± 0.1 
 
83 ± 2 
 
LDS 1.5 6.8 ± 0.2 
 
91 ± 1 
 
CS 0.5 2.1 ± 0.1 
 
89 ± 0.1 
 
CS 1 4.5 ± 0.1 
 
95 ± 0.3 
 
CS 1.5 7.4 ± 0.1 
 
97 ± 0.2 
 
HP 0.5 2.2 ± 0.1 90 ± 0.3 
HP 1 4.7 ± 0.2 94 ± 1 
HP 1.5 7.3 ± 0.1 97 ± 0.1 
 
 
 
 
                                                 
5
 Theoretical content of MgCO3, trehalose and BP was ~3, 3 and 4 % w/w in the formulations, respectively. 
Data reported as mean ± SE, n = 3; total microsphere mass in loading solution was ~20 mg. 
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Figure 4-4 : A fit of the % w/w LYZ loading of optimal ASE BP-PLGA microspheres as a function of the 
LYZ loading concentration. Theoretical content of BPs, trehalose and MgCO3 was ~ 4, 3 and 3 %w/w, 
respectively, in the formulations. 
 
4.4.5 Distribution of Biomimetically ASE Cy5-LYZ in HDS(FITC)-PLGA 
microspheres 
 
To visualize the distribution of BP and biomimetically encapsulated protein, we used 
FITC-HDS and Cy5-LYZ. In theory, the FITC-HDS would be uniformly distributed in 
the microspheres during the double emulsion manufacturing process. The evenly 
distributed BP would allow for uniform binding and loading of protein, which could 
allow for a slow and uniform controlled release.  
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Figure 4-5 : Distribution of HDS(FITC) in microspheres. 
 
 
Figure 4-6 : Distribution of ASE Cy5-LYZ in HDS-PLGA microspheres loaded from 1ml of 1mg/ml Cy5-
LYZ in 10 mM phosphate solution (pH 7). 
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Upon imaging the lyophilized FITC HDS-PLGA microspheres, FITC-HDS was un-
evenly distributed in the microspheres (Figure 4-5). It was pre-dominantly localized in 
the outer regions of the microspheres; the inner pores contained comparatively lower 
amounts. Similarly, larger amounts of Cy5-LYZ were found on the outer surface and 
regions of the biomimetically loaded ASE microspheres (Figure 4-6). Attempts to 
quantify the degree of overlap between FITC-HDS and Cy5-LYZ were limited due to 
issues associated with the use of FITC. 
   
Volumetric images were generated by combining multiple images obtained at different 
focal lengths. The image shows that LYZ was able to enter the porous microsphere 
extensively, with greater distribution in the outer areas of the particle (Figure 4-7). This 
was expected, as during the loading process LYZ was diffusing into the microsphere 
from the liquid-microsphere interface, via the surface pores. Red domains indicate areas 
of high LYZ concentration near the surface of the HDS-PLGA microsphere. Ideally, 
uniform distribution of LYZ in the microsphere would allow for a long acting release 
formulation with slow continuous release, without a large burst release. This suggests that 
improving the distribution of the biomimetically ASE Cy5-LYZ could potentially 
improve first-order type release kinetics, as described below. 
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Figure 4-7 : Distribution of ASE Cy5-LYZ in HDS-PLGA microsphere. Volumetric image was obtained by 
combining images taken at different heights. Red regions indicate regions of very high concentration of 
Cy5-LYZ. 
 
 
4.4.6 Release Kinetics of LYZ from BP-PLGA Microspheres 
    
The release kinetics of biomimetically encapsulated LYZ from sulfated BP-PLGA 
microspheres was initially investigated in 1 ml PBS at pH 7.4 (Figure 4-8). PBS was used 
to avoid initial complications associated with LYZ quantification, due to overlap of 
Tween 80 and LYZ peaks during SE-HPLC analysis. 
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4.4.6.1 Effect of LYZ Loading Concentration 
 
Across all formulations, the cumulative release plateaued at around day 7 and increased 
after 28 days of release (Figure 4-8). The first stage of this two-phase release would be 
expected to be driven by diffusion of the LYZ, which was either poorly encapsulated or 
released from the microsphere prior to healing of newly formed pores created during 
drying or initial hydration of the microspheres. After this initial phase, continuous release 
could be sustained by the presence of the MgCO3 excipient, which reacts with the 
degradation products to create osmotic pressure and new pores in the polymer matrix. 
The kinetics is also likely governed by the BP-LYZ interactions and the movement of 
complexes and soluble LYZ, through the pore network.  
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Figure 4-8 : LYZ release profiles in 1 ml PBS (pH 7.4) at 37 °C quantified by SE-HPLC at 282 nm. ASE 
BP-PLGA microspheres were loaded from LYZ in 10 mM phosphate buffer at concentrations of 0.5(─●─), 
1(─○─) and 1.5(─▼─) mg/ml. The values are expressed as mean ± SD n=3; total microsphere mass in 
release media was ~ 18 mg.  
 
BP-PLGA microspheres loaded with 1.5 mg/ml LYZ had the highest rate of release and 
extent (≈ 80%) of the self-encapsulated LYZ for all BP-PLGA microspheres, except 
HDS-PLGA. Overall, HDS-PLGA microspheres had some of the lowest burst release, as 
well as rate and extent of long-term release. They were noted to release ~ 35-45 % of the 
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encapsulated LYZ. Whereas, LDS-PLGA formulations exhibited a higher rate and extent 
of release when compared to HDS loaded at 1.5 mg/ml LYZ. LDS-PLGA formulations 
loaded from 0.5 and 1 mg/ml LZY solutions released ~ 28-40 % LYZ. CS-PLGA 
formulations had the highest burst release (> 40 %) across the sulfated BP-PLGA 
microspheres investigated. They were observed to release ~ 60-80 % of the encapsulated 
LYZ over 60 days. HP-PLGA formulations were also observed to have very high burst 
release, and released ~ 60-80 % of the LYZ. 
 
4.4.6.2 Effect of Ionic Strength 
 
To evaluate the role of BP-LYZ interactions on release kinetics, the ionic strength of the 
release media was varied. In-vitro release of LYZ loaded BP-PLGA microspheres were 
quantified in 1ml of PBS+0.3 M NaCl and PBS+0.6 M NaCl. Due to the electrostatic 
component of the BP-Protein interaction, the rate and extent of LYZ released was 
expected to increase with ionic strength of the release media. This was verified, as the 
rate and extent of LYZ release was found to increase across all ASE formulations, with 
increasing ionic strength. This suggests that the ionic interaction played an important role 
in determining the protein release. The solubility of lysozyme has been shown to slightly 
increase with increasing NaCl concentration, which is in the  middle of the Hofmeister 
series [16]. Thus, it is unlikely that the progressively increasing amount of lysozyme 
release with the NaCl concentration was due to a salting-in effect exerted to lysozyme 
solubility within the microspheres. It is also noted that the increase of the salt 
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concentration in the medium slowed down polymer degradation [17]. Park et al. have 
shown that LYZ in-vitro release kinetics are influenced by presence of NaCl, suggesting 
that the NaCl disrupts the ionic interactions between PLGA and protein [18]. Lee et al. 
have also reported similar effects of ionic strength on release of BSA and histone [19].   
Thus, it is highly probable that the faster lysozyme release due to NaCl for BP-PLGA 
microspheres cannot be only attributed to the disruption of ionic interaction between 
lysozyme and PLGA, but also due to unraveling of BP-LYZ complexes, as previously 
shown (Figure 2-3,Figure 2-4 and Figure 2-5). 
 
Upon examining [LYZ released/mass of BP-PLGA microspheres] versus time, the 
amount and rate of LYZ release increased with ionic strength across all ASE 
formulations. No significant differences were seen in the rate of release amongst the 
LDS-PLGA, HP-PLGA and CS-PLGA microspheres loaded with different concentrations 
of LYZ in PBS, PBS+0.3M NaCl and PBS+0.6M NaCl. In PBS, clear differences were 
seen in the rate of LYZ released amongst the HDS-PLGA microspheres loaded with 
different LYZ concentrations (Figure 4-9). The rate decreases with the decreasing LYZ 
loading solution concentration, suggesting that the HDS:LYZ ratio during loading is 
indeed an important variable governing LYZ release kinetics.  
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Figure 4-9 : Representative plots showing the effect of ionic strength on LYZ release in 1 ml PBS (pH 7.4) 
at 37 °C. Trends similar to LDS-PLGA were observed for CS-PLGA and HP-PLGA. LYZ quantified by 
SE-HPLC at 282 nm. ASE BP-PLGA microspheres were loaded from 10 mM Phosphate (pH 7) LYZ 
loading solutions with conc. of 0.5(─●─), 1(─○─) and 1.5(─▼─) mg/ml. The values are expressed as 
mean ± SE; n = 3; total microsphere mass in release media was ≈ 18 mg. (Top row): Release in PBS. 
(Middle row) Release in PBS + 0.3M NaCl. (Bottom row) Release in PBS + 0.6 M NaCl.  
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4.4.6.3 Effect of Release Volume 
 
To study the effect of volume on kinetics of release, LDS-PLGA microspheres loaded 
with ≈ 2% w/w LYZ solution were incubated in PBS at pH 7.4 over a range of volumes 
(0.5 – 20 ml), with the LYZ release being quantified by SE-UPLC. The rate and extent of 
LYZ release from LDS-PLGA was found to increase as the volume of release was 
increased from 0.5 ml to 5ml (Figure 4-10). LYZ release from LDS-PLGA microspheres 
over 60 days was ~ 40, 68, and 85 % for 1 ml, 3 ml and 5 ml, respectively. LYZ release 
in 10, 15, and 20 ml was also quantified up to 3 days, beyond which the LYZ 
concentration in the release media could not be detected by SE-UPLC. Upon comparing 
the LYZ release in 5, 10, 15 and 20 ml, no significant differences were seen. This 
suggests that sink conditions were attained at and above 5 ml of PBS for ≈ 18 mg of LYZ 
loaded LDS-PLGA microspheres. This effect of volume should be considered while 
estimating release kinetics during in-vitro experiments  
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Figure 4-10 : LYZ release profiles from LDS-PLGA microspheres in PBS (pH 7.4) at 37 °C, quantified by 
SE-UPLC at 282 nm, as a function of release media volume. Microspheres were loaded from 1 mg/ml LYZ 
in 10 mM phosphate buffer (pH 7). The values are expressed as mean ± SE; n=3; microsphere mass in 
release media was ~ 18 mg. Insert - Release in high volume was not feasible beyond 3 days due to poor 
quantification of protein at very low concentration via SE-UPLC.  
 
This effect of volume on release kinetics has not been reported in the literature, to the 
best of our knowledge. We initially hypothesized the effect could possible due to the 
solubility of BP-LYZ complexes inside the PLGA microspheres. This dissolution of the 
complex would be expected to increase as the volume is increased, allowing the free LYZ 
to leach out of the microspheres, as the volume is increased upto the level of sink 
conditions. 
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Figure 4-11 : LYZ release profiles from LDS-LYZ complexes in PBS (pH 7.4) at 37 °C, quantified by SE-
UPLC at 282 nm, as a function of release media volume. The values are expressed as m as mean ± SE; n=3; 
mass of complexes in release media was ~ 4 mg. 
 
To check the validity of the hypothesis, release kinetics of LDS-LYZ complexes were 
investigated at 0.5 ml, 1 ml, and 3 ml (Figure 4-11). The complexes were seen to release 
~ 30 % of the LYZ over 140 h. Contrary to our hypothesis, no significant differences 
were seen in the release kinetics of LYZ amongst the 3 volume investigated. In addition, 
to investigate the effect of free LDS on release kinetics, LYZ release studied in PBS + 10 
mg/ml LDS. As expected, LDS slowed down the release of LYZ, possible due to its 
ability to bind and precipitate LYZ from solution. LYZ release in PBS + LDS was only ~ 
12 %, in comparison to nearly ~ 30 % in PBS. 
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4.4.6.4 Release Kinetics of LYZ in Optimized Release Media Volume 
 
From our data, we identified HDS-PLGA formulations to be ideal for evaluating 
controlled release formulations as they consistently have amongst the highest loading 
(and encapsulation efficiency) and the lowest burst release of all formulations 
investigated. The HDS-LYZ complexes also had shown excellent release characteristics 
to be used for developing long-acting-release formulations (Figure 2-2). The data further 
suggests that the rate of release could be adjusted by changing the HDS:protein ratio 
during ASE. In addition, the high Mw of HDS should minimize any potential leaching and 
complications during ASE of proteins.    
 
Based upon the release data above, ~ 18 mg of HDS-PLGA (loaded with 1 ml and 1.5 
mg/ml LYZ) formulations were incubated in 5 ml PBST to evaluate LYZ release kinetics 
and activity of released LYZ (Figure 4-12). It was not feasible to use a higher release 
volume as released LYZ concentrations would be too low to be quantified using SE-
UPLC beyond 3 days of release. HDS-PLGA formulations loaded with 1.5 mg/ml were 
found to have good release kinetics with ~ 60% released over 21 days. The remaining 
protein was gradually released over the period monitored, leading to ~ 73-80% of 
encapsulated protein being released over 55 days. The average activity of the released 
LYZ was found be > 90 % during the entire course of release experiment. 
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Whereas, the formulations loaded with 1 mg/ml LYZ were found to have comparatively 
slower LYZ release kinetics. Over 21 days, ~ 38 % of the encapsulated LYZ was released 
after which the release slowed down to release ~ 48 % of the LYZ in 55 days. The 
average activity of the released LYZ was ~ 90 % over 14 days. The data clearly 
demonstrates the role of loading solution concentration in governing LYZ release kinetics 
of LYZ form HDS-PPLGA microspheres, with higher concentration leading to faster 
release kinetics. 
 
Time ( Days)
0 10 20 30 40 50 60
%
 C
u
m
u
la
ti
v
e
 L
Y
Z
 R
e
le
a
s
e
0
20
40
60
80
LS 1 mg/ml
LS 1.5 mg/ml
Time (Days)
0 10 20 30 40 50 60
A
c
ti
v
e
 L
Y
Z
 (
%
)
60
80
100
120
Figure 4-12 : LYZ release profiles in PBST (PBS with 0.02% Tween 80) quantified by SE-UPLC at 282 
nm. ASE HDS-PLGA microspheres were loaded from 1.5 mg/ml LYZ in 10 mM phosphate buffer (pH 7). 
The values are expressed as mean ± SE; n = 3; microsphere mass in solution was ~ 18 mg. 
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4.4.7 Active Self Encapsulation of growth factors by BP-PLGA 
 
Based upon the success of encapsulating LYZ in sulfated BP-PLGA microspheres via 
ASE, the feasibility of the biomimetic paradigm was verified by the encapsulation of 
recombinant human FgF-20 and VEGF165 (Table 4-4). Loading efficiencies of >80% 
with ~2% (w/w) were obtained for FgF-20, across all the BP formulations analyzed. 
These results are very encouraging as encapsulation was achieved in presence of 0.5 M 
Arg in loading solution to overcome solubility and stability issues associated with FgF-
20. Upon biomimetic ASE of VEGF by HDS-PLGA microspheres, ~ 4% (w/w) loading 
was obtained with nearly 75% efficiency. This was achieved in presence of 275 mM 
trehalose, to improve stability of the VEGF during the loading and incubation.   
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Table 4-4: Biomimetic ASE of growth factors in BP-PLGA microspheres
6
 
 
 
 
 
 
                                                 
6
 Theoretical content of MgCO3, trehalose and BP was ~3, 3 and 4 % w/w in the formulations, respectively. 
ASE of FgF-20 was from 1ml of 0.5 mg/ml FGF-20 loading solution (0.5M arginine, 0.05 M sodium 
phosphate and 0.08% polysorbate). ASE of VEGF in HDS-PLGA microspheres was from 1ml of 1 mg/ml 
VEGF loading solution (5 mM succinate buffer, 275 mM trehalose and 0.01% polysorbate 20). Mean ± SE, 
n = 3; total microsphere mass in loading solution was ~20 mg. 
 
 
BP 
 
 
Loading Solution 
 
                Loading         Encapsulation Efficiency 
     (% w/w)                                  (%) 
 
HDS  
 
0.5 mg/ml FgF-20 
 
2.3 ± 0.1 
 
 
87 ± 1 
 
 
LDS  
 
0.5 mg/ml FgF-20 
 
2.1 ± 0.1 
 
 
84 ± 1 
 
 
CS  
 
0.5 mg/ml FgF-20 
 
1.9 ± 0.2 
 
85 ± 2 
 
 
HP  
 
0.5 mg/ml FgF-20 
 
2.1 ± 0.1 
 
 
81 ± 1 
 
 
HDS  
 
1 mg/ml VEGF 
 
4.1 ± 0.4 
 
 
73 ± 6 
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4.4.7.1 Release kinetics of VEGF from HDS-PLGA microspheres 
 
The release kinetics of VEGF loaded HDS-PLGA was evaluated in 5 ml PBST + 1% 
BSA, with full media replacement (Figure 4-11). BSA was added in the release media to 
improve stability of released VEGF and prevent non-specific adsorption to the release 
vessel [20]. Over 42 days, nearly 72 % of encapsulated VEGF was released in an 
immunoactive form. The released VEGF retained its ability to bind to heparin (> 92 % 
relative to immunoreactive VEGF over 23 days), consistent with retaining a very high 
fraction of the growth factor’s native structure during long-term release. The release 
kinetics were found to be slightly faster when compared to LYZ, which could have 
resulted from the presence of 275 mM trehalose and 10 mg/ml BSA in the external 
loading solution, which reasonably could affect the VEGF-HDS interaction. Release 
kinetics of FgF-20 was not characterized because of the lack of a suitable release assay 
for a viable release media. 
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Figure 4-13 : VEGF release profile from HDS-PLGA microspheres in 5 ml PBST (pH 7.4 with 1% BSA), 
were quantified using ELISA. ASE HDS-PLGA microspheres were loaded from 1 ml of 1.0 mg/ml VEGF 
solution (5 mM succinate bufer, 275 mM trehalose and 0.01% polysorbate 20). 
 
4.4.8 Efforts to improve LYZ release profile 
 
In an effort to improve protein stability, our research group has tested a number of basic 
salts to control the pH and prevent aggregation of protein inside PLGA [21, 22]. During 
the process, the choice of base and content was also found to influence the release 
kinetics of the encapsulated protein. Increasing base content was found to be an effective 
means of increasing rate and total amount of release. Use of base with higher solubility 
was found to improve water uptake in the PLGA matrix, allowing for faster protein 
release. On comparing Mg(OH)2, MgCO3, ZnCO3, and Ca3(PO4)2; Mg(OH)2 was found 
to perform poorly in PLGA microspheres due to its poor solubility whereas, MgCO3 was 
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identified to be much better at controlling the microclimate [21]. ZnCO3 and Ca3(PO4)2 
are comparatively weaker bases, which can potentially lead to higher non-covalent 
aggregates as compared to Mg(OH)2 [22]. PLGA millicylinders with ZnCO3 were found 
to have faster BSA release kinetics when compared to Ca3(PO4)2. Thus, to improve the 
release characteristics of biomimetically ASE LYZ from HDS-PLGA microspheres, 
formulations with ZnCO3 and MgCO3 were evaluated. These microspheres were prepared 
with a new batch of polymer and were found to have different pore closing properties, 
than all formulations discussed above and in earlier chapters. Increasing the base content, 
as discussed above, could potentially allow for a better release profile with a slow 
continuous release and a less pronounced lag phase.  
 
The microspheres were loaded with 1 mg/ml LYZ in phosphate buffer (pH 7) (Table 
4-5). Microspheres with MgCO3 encapsulated most of the LYZ from the solution; 
whereas formulation with higher ZnCO3 content was more efficient at encapsulating 
LYZ. This could probably be related to the improved pore structure seen with higher base 
content. 
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Table 4-5: Biomimetic ASE of LYZ in HDS-PLGA microspheres
7
 
 
 
Release kinetics were evaulted in 5 ml PBST (pH 7.4)  at 37 °C, with complete media 
repalcement (Figure 4-14). Over 24 days, formulations with MgCO3 released ~ 14-16 % 
of the encapsulted LYZ. Slight differences in release profile could be observed with 
varying base content, but no significant conclusions can be drawn from the data. LYZ 
release profile from formulations with 3.1 and 8.3 % (w/w) ZnCO3 were nearly identiocal 
over 24 days. Overall, formaultions with MgCO3 were observed to have a faster rate and 
extent of release over the time period of the experiment. 
                                                 
7
 Theoretical content of trehalose and BP was ~ 3 and 4 % w/w in the formulations, respectively. HDS-
PLGA microspheres were loaded from 1 mg/ml LYZ in 10 mM phosphate buffer (pH 7).Data reported as 
mean ± SE, n = 3; total microsphere mass in loading solution was ~25 mg. 
 
 
 
BP 
 
 
Base 
(%w/w) 
 
                             LYZ Loading                                        
           (% w/w)                    Encapsulation 
Efficiency (%) 
HDS 3.1 % MgCO3 4.4 ± 0.1 
 
99.6 ± 0.05 
 
HDS 7.7 % MgCO3 4.57 ± 0.3 
 
99.7 ± 0.01 
 
HDS 3.1 % ZnCO3 4.14 ± 0.1 89.4 ± 0.8 
 
HDS 8.3 % ZnCO3 4.5 ± 0.2 
 
99.9 ± 0.02 
 
122 
 
Time (Days)
0 10 20 30 40 50 60
%
 C
u
m
u
la
ti
v
e
 L
Y
Z
 R
e
le
a
s
e
0
2
4
6
8
10
12
14
16
18
20
3% MgCO3
8% MgCO3
3% ZnCO3
8% ZnCO3
 
Figure 4-14 : LYZ release profiles in PBST (PBS with 0.02% Tween 80) quantified by SE-UPLC at 282 
nm. ASE HDS-PLGA microspheres were loaded from 1ml of 1mg/ml LYZ in 10 mM phosphate buffer (pH 
7). The values are expressed as mean ± SE; n = 3; microsphere mass in solution 
 
The release kinetics of LYZ from HDS-PLGA microspheres made from the new batch of 
polymer was found to be slower than microspheres made with the older batch of PLGA. 
This highlights one of the major issues in the field, namely the change in properties of the 
polymer with every batch of PLGA. 
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4.5 Conclusions 
 
The biomimetic paradigm provided excellent LYZ, VEGF165 and FgF-20 loading, 
encapsulation efficiency and potential for long-term release. ASE of LYZ could be 
achieved at ~ 7 % (w/w) with ~ 97 % encapsulation efficiency. This high efficiency of 
loading is remarkable for a loading mechanism primarily driven by diffusion. 
Subsequently, we were able to demonstrate excellent release profile and stability over 60 
days, of the LYZ released form biomimetically ASE BP-PLGA microspheres. 
 
 The ~ 4 % w/w loading of VEGF achieved by ASE is significantly higher [23-25], than 
the literature where the VEGF was included in the first emulsion, during the preparation 
of PLGA particles. The encapsulation efficiency is also higher than reported in most 
cases [26-28]. This is significant as our methodology allows the protein to be loaded after 
the formation of the PLGA microparticle, protecting it from harsh conditions and 
processes associated with manufacturing. The release kinetics reported here are 
comparable to the literature with ≈ 70 % of immunoreactive VEGF released over 30 days 
with excellent stability and without significant losses to heparin binding affinity, making 
it a promising delivery system. LYZ release from PLGA has been studied extensively, 
and it is reported to suffer from stability issues when encapsulated with traditional 
paradigms [18, 29-31]. In our work, we were able to demonstrate high LYZ loading and 
encapsulation efficiency with excellent release profile and stability over 60 days. Thus, 
our data demonstrates the potential for using biomimetic ASE for developing long-
acting-release products for protein delivery. 
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CHAPTER 5 PROTEIN-BIOPOLYMER INTERACTIONS 
 
5.1 Abstract 
 
Aggregation and stability of biologics are two of the major hurdles impeding 
development of injectable protein formulations. In this chapter, we explored the potential 
of using biopolymers [high molecular weight dextran sulfate (HDS), low molecular 
weight dextran sulfate (LDS), chondroitin sulfate (CS), and heparin (HP)] as stabilizing 
agents for the development of pharmaceutical formulations of proteins [lysozyme (LYZ), 
human growth hormone (hgH), vascular endothelial growth factor165 (VEGF) and 
fibroblast growth factor (FgF-20)]. Using circular dichroism, isothermal titration 
calorimetry, differential scanning calorimetry, and intrinsic fluorescence, we compared 
the protein-biopolymer interactions to commonly used polyions like phytic acid (PA) and 
sucrose octasulfate (SO). LYZ-BP interactions were found to be enthalpically driven, 
with a Gibbs free energy of ~ 30-40 kJ/mol. BPs were found to change the secondary 
structure of LYZ. Thermal melts of LYZ were also analyzed in the presence of BPs. BPs 
were also observed to reduce the apparent Tm of LYZ and hgH in solution. Thus, the data 
suggests that suitably selected BP could potentially be used to formulate proteins, which 
tend to aggregate and self-associate.  
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5.2 Introduction 
 
Biologics are rapidly emerging as a major class of drug products with expected sales of 
nearly $200 billion by 2017, representing 19-20% of total market value [1]. Proteins, 
antibodies and vaccines account for a total sales of ~ $108 billion in 2012, with 29 
blockbusters amongst their ranks [1, 2]. In addition, increasing healthcare costs make it 
essential to develop inexpensive yet robust formulations, especially with the expected 
growth of biosimilars in the near future. A number of challenges associated with 
formulation development need to be addressed for this to happen. Stability and 
aggregation of biologics in solution is one of the major challenges being faced during 
production and storage of injectable biologics [3, 4]. Aggregation causes not only loss of 
therapeutic dose, but also leads to potentially adverse immunogenic reactions [5-7].  
 
Numerous studies have indicated that both specific and non-specific elements govern 
interactions between polyions and proteins. The interaction of surface proteoglycans to 
growth factors have been extensively reviewed in the literature [8, 9]. Angiogenic growth 
factors are engaged in multiple interactions in the extracellular environment and on the 
extra-cellular surface of cells. They bind to a variety of free or immobilized proteins, 
polysaccharides, and complex lipids present in the extracellular milieu and these 
interactions may affect their stability, integrity, bioavailability and diffusion [10]. They 
are found in body fluids as circulating complexes or immobilized in the extra-cellular 
matrix (ECM) and in the sub-endothelial lamina of micro-and macrovasculature [8]. The 
ECM is largely composed of complex polysaccharides, with glycosaminoglycans (GAGs) 
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being one of the major classes of polysaccharides. They are known to bind and regulate a 
number of distinct proteins, including chemokines, cytokines, growth factors, 
morphogens, adhesion molecules and enzymes [8, 9, 11].  
 
In the previous chapters, we have discussed the use of BP for stabilizing and protecting 
proteins embedded in PLGA matrix. In this chapter, we sought to understand the nature 
of interactions between the BPs and proteins. The thermodynamics of the interactions 
were investigated using a variety of analytical techniques; we explored the potential of 
using BPs as stabilizing agents for the development of pharmaceutical formulations of 
bio-macromolecules. Using multiple analytical techniques, in addition to elucidating the 
nature of interactions, we have attempted to develop a rationale for selecting polyions for 
developing pharmaceutical formulations of proteins. We compared the interactions of 
BPs to commonly used polyions like phytic acid and sucrose octasulafate [12-14]. The 
availability and ease of use made lysozyme (LYZ) the ideal candidate to study the 
interactions with BP using a number of techniques. Its interactions were studied using 
circular dichroism (CD), isothermal titration calorimetry (ITC), differential scanning 
calorimetry (DSC), and intrinsic fluorescence (IF). The cost, availability, and buffer 
composition limited the use of these techniques for human growth hormone (hgH), 
vascular endothelial growth hormone (VEGF) and fibroblast growth factor 20 (FgF-20).  
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5.3 Materials and Methods 
 
5.3.1 Materials 
 
High molecular weight (~ 500 kDa) dextran sulfate (HDS), low molecular weight (~15.5 
kDa) dextran sulfate (LDS), chondroitin sulfate (~ 63 kDa, shark cartilage) (CS), porcine 
heparin (~18 kDa) (HP), Phytic Acid (PY) sodium salts were purchased from Sigma-
Aldrich. Suscrose octasulfate (SO) was bought from Toronto Research Chemicals 
(Canada). Lysozyme (chicken egg white) was also purchased from Sigma-Aldrich. FgF-
20 was obtained from the NCI-BRB Preclinical Repository. VEGF and hgH were 
obtained as gifts from Genentech (CA, USA). All other reagents, common solvents and 
supplies were obtained from Sigma-Aldrich, unless otherwise specified. 
 
5.3.2 Circular Dichroism and Fluorescence Spectroscopy 
 
CD and fluorescent measurements were made using the JASCO 815 spectrophotometer 
(JASCO, USA) equipped with peltier temperature controller. CD spectra were collected 
from 190 to 270 nm at the speed of 50 nm/min, resolution of 0.1 nm and a DIT of 1 sec. 
Thermal melts were obtained at 5C intervals from 20-85°C, with a heating rate of 
15°C/hr and a 5 min equilibration time. Five cycles of spectra were collected and 
reported as average.  
 
131 
 
Fluorescent measurements were obtained over 305-440 nm via excitation of Trp residues 
at 295nm with a resolution of 1 nm. Five cycles of spectra were collected and reported as 
average.  
 
5.3.3 Differential Scanning Calorimetry 
 
Thermographs were collected with the TA Instruments (USA) nano series differential 
scanning calorimeter. Data was collected from 20 – 95 ºC at a scan rate of 1 ºC /min 
under a pressure of 42 psi. Appropriate controls were also scanned, and these 
thermographs were subtracted from sample melts before data analysis using 
NanoAnalyse. 
 
5.3.4 Isothermal Titration Calorimetry 
 
Calorimetric titrations were performed with TA Instruments (USA) nano series 
isothermal titration calorimeter. 400 µl of protein solution was titrated against 50 µl of 
BP solution at the specified temperature with the stirrer set at 250 rpm. The reference cell 
contained 400 µl of purified water, and all solutions were degassed prior to use. 
Appropriate heats of dilution were also obtained using controls, and were subtracted from 
sample data. The corrected data were analyzed using TA’s NanoAnalsye software and 
were fit to an independent set of multiple biding sites. Samples were run in triplicates.   
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5.4 Results and Discussion 
 
5.4.1 Protein Stabilization by Excipients 
 
Protein stability is a major issue with development of biopharmaceuticals, but the free 
energy of the native protein conformation is only 5-20 kJ/mol more stable than the 
denatured biologically inactive form [15]. A wide range of excipients have been 
developed to stabilize and protect the native state of the protein for pharmaceutical 
development [3, 16-19]. 
 
Electrostatic interactions, van der Waals forces, hydrogen bond, and hydrophobic 
interaction are the major interactions governing protein structure and amino acid 
interactions. Electrostatic interactions occur between charged atoms or molecules, which 
depends on environmental pH, and ionic strength. Van der Waals interactions consist of 
interactions between two permanent dipoles, permanent and induced dipoles, and two 
induced dipoles. Hydrogen bonds are strong dipole-dipole interactions, which arise due to 
electrostatic attraction between polar molecules when hydrogen is bound to a strong 
electronegative atoms. It plays a crucial role in determining protein structure and is 
reported to be 2-10 kcal/mole [20]. Hydrophobic interactions are created by the 
minimization of contact between non-polar and polar species. It is known to bring about 
preferential hydration of proteins. It is a major determinant of protein structure and 
stability.  
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Protein interactions with co-solvents have been widely studied. A specific stabilizing 
ligand binds to the native and functional protein, thereby directly stabilizing it. It can also 
potentially bind to the denatured state to prevent aggregation. An osmolyte is usually a 
small molecule, which also preferably interacts with the native form over the unfolded 
form, thus increasing the unfolding energy [16, 21]. Arginine's role in protein stability is 
still not very clearly understood and a number of different mechanisms have been 
proposed. It is known to suppress aggregation by preferably binding to denatured state, 
decrease non-specific adsorption of proteins, stabilize proteins via hydrophobic 
interactions, etc [18, 21, 22]. Denaturants are known to change the secondary and tertiary 
structure of native proteins they bind to [16]. They are known to denature the protein via 
direct chemical attacks or strong changes at the protein-solution interfaces to bring about 
protein unfolding and precipitation.  
 
5.4.2 Proteins and Biopolymers 
 
As discussed in the previous chapters, specificity of GAG-protein interactions are driven 
by the ionic interactions between sulfate and carboxylate on GAG's and basic amino 
acids on the protein [8]. The three-dimensional conformations of the GAG and protein 
determine the exposed sulfate, carboxylate and amino acid groups [9]. Strong ionic 
interactions are expected between GAGs and proteins [8]. Clusters of positively charged 
basic amino acids on proteins form ion pairs with spatially defined negatively charged 
sulphate or carboxylate groups on heparin chains. Glycosaminoglycans interact with 
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residues that are prominently exposed on the surface of proteins. The main contribution 
to binding affinity comes from ionic interactions between the highly acidic sulphate 
groups and the basic side chains of arginine, lysine and, to a lesser extent, histidine [23]. 
The interactions of GAGs with proteins also involve a variety of different types of 
interactions, including van der Waals (VDW) forces, hydrogen bonds, and hydrophobic 
interactions with the carbohydrate backbone. It has also been observed that heparin-
binding domains contain amino acids such as asparagine and glutamine, which are 
capable of hydrogen bonding. The affinity of heparin-binding proteins for heparin/HS 
was also enhanced due to the presence of polar residues with smaller side chains like 
serine and glycine.  
 
Various growth factors bind to the ECM of target tissues by forming tight complexes 
with sulphated-glycosaminoglycans [24]. Variations of the fine structure of the GAG 
chains may allow cells to control their responses to individual growth factors and to 
change the specificity of their response to different members of the growth factor family. 
Reports indicate that GAG's mediate the activity of FGF-2 by inducing dimer formation 
and transient dimerization though specific interactions with FGF-2 and its receptor [25, 
26]. No significant change in the structure of FGF-2 was observed upon binding. 
Sulphated-GAG's bind to different VEGF isoforms, exerting multifaceted effects. They 
contribute to VEGF accumulation in the ECM and acts as EC core-receptors for VEGF  
[27]. The effect of GAG's on VEGF165 would depend upon the size of the chains, high 
molecular weight chains increase VEGF binding to receptors while the lower molecular 
weight chains inhibit pro-angiogenic activity of VEGF165. VEGF is one of the most well 
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studied growth factor involved in EC migration, mitogenesis, sprouting, and tube 
formation [28]. Recombinant human vascular endothelial growth factor (rhVEGF) 
behaves similar to native VEGF in terms of its binding to heparin and its biological 
activity. RhVEGF is a homodimeric protein consisting of 165 amino acids per monomer 
with a molecular weight of 38.3 kDa and a pI of 8.5. The protein consists of 2 domains, a 
receptor-binding domain (residues 1-110) and a heparin-binding domain (residues 111-
165) [29]. 
                                                                              
Heparin consists of repeating units of 1→4 linked pyranosyluronic acid and 2-amino-2-
deoxyglucopyranose (glucosamine) residues [9]. The uronic acid residues typically 
consist of 90%L-idopyranosyluronic acid (L-iduronic acid) and 10% D-
glucopyranosyluronic acid (D-glucuronic acid). It has been studied extensively due to its 
well understood functions in anti-coagulation and is known to be highly evolutionarily 
conserved with similar structures found in a broad range of vertebrate and invertebrate 
organisms [23]. 
 
5.4.3 Effect of BPs on Protein Structure 
 
Circular Dichroism uses the differences in absorption of left versus right handed 
polarized light to determine structural element of proteins. The secondary structure of 
proteins can be analyzed in the far –UV region (190-250nm). If data from the entire range 
is not available, the reliability of structural quantification is questionable but the 
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compassions of spectra are not compromised. In contrast to far UV region, near CD 
region provides information about the columbic interactions between dipoles, structural 
information via relative polarity and hydrogen bonding characteristics of environment 
surrounding Trp, Phe, Tyr, and Cys residues [30]. 
 
Intrinsic fluorescence of protein is a very sensitive technique to study protein 
conformational transitions, subunit association, substrate binding, or denaturation [31, 
32]. The relatively rare amino acids phenylalanine (Phe), tyrosine (Tyr) and tryphophan 
(Try) are all fluorescent. Phe has a very poor quantum yield, so its emission is rarely 
observed for proteins. The emission maximum of Trp is highly sensitive to local 
environment whereas Try maximas are insensitive to its local environment. Trp can be 
selectively excited at 295-300 nm and has been widely used to study the polarity of its 
environment. At 295 nm, Trp emission spectra reflect the average environment of the 
residues in the protein. Trp, in a completely non-polar environment has a blue shifted 
structure characteristic of indole in cyclohexane, while on being hydrogen bonded or 
exposed to water, its emission shifts to longer wavelengths.   
 
5.4.3.1 Effect of BPs on LYZ Melt 
LYZ thermal melts were used to analyze the change in structure in the presence of BP. 
The CD spectra of native LYZ has been reported to contained two minima at 208 nm and 
222 nm, characteristic of a predominantly α-helical structure [33]. The 208 nm band is 
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known to correspond to π–π* transition of the α-helix and the 222 nm band due to n–π* 
transition for both the α-helix and random coil.  
To estimate the ability of BPs to stabilize the LYZ, thermal melts were obtained at 42X 
(BP:LYZ). The spectra of the native LYZ shows a loss of the minima and the maxima at 
190 nm, indicating a change in the native α-helical structure at 75 °C and above. This 
suggests that the native protein undergoes a structural transition due heat denaturation 
around 75 °C. In the presence of HDS, the minima were larger in 208-220 nm regions, 
suggesting that the α-helical content is larger and the LYZ undergoes a structural 
transition where helical content is lost, beyond 50 °C. The presence of LDS reduced the 
minima and brought about a larger transition in LYZ structure beyond 50°C. In presence 
of HP, the spectra were found to be similar to LDS, with a major denaturation event 
accompanied with a loss of helical content beyond 60°. A similar transition in the spectra 
of LYZ was seen in presence of PA, beyond 65 °C. Among all the BP, SO increased the 
minima in the 208-220 nm and maintained the structure of LYZ throughout the melt.     
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 (a)                                                                                          (b)        
                                                                   
(c)                                                                                      (d) 
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     (e)                                                                                      (f) 
 
Figure 5-1 : CD Spectra of (a) 0.12 mg/ml LYZ in 10 mM Phosp. Buff (b) 25X LDS (c) 25X HDS (d) 25X HP (e) 25X OS (f) 
25X PA 
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5.4.3.2 Effect of BPs on LYZ structure 
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Figure 5-2 : Effect of BPs on 0.012 mg/ml LYZ in phosphate buffer (pH 7) with 25 times mass excess. 
 
The effect of the BPs on the secondary structure of the LYZ was studied at 25 times mass 
excess by CD (Figure 5-2). HDS and SO were observed to increase the minimas in 208-
222 nm region, suggesting that the λ content is increased. This could be attributed to the 
ability of larger BPs to lock LYZ into particular conformations via interactions with a 
larger number of charges on the molecular chain. Comparatively, smaller BPs were noted 
to have a smaller effect on the LYZ secondary structure. 
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The effect of the BPs was also studied at different mass excess to further study the 
change in LYZ structure (Figure 5-3). As expected, increasing amount of BP increases its 
ability to bring about the change in structure of LYZ as discussed above (Figure 5-2).    
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Figure 5-3 : Representative CD profiles of 0.012 mg/ml LYZ in phosphate buffer (pH 7) with 20 and 40 
times mass excess BPs. 
 
Similarly, the effect of BPs on the tertiary structure of LYZ was studied with intrinsic 
fluorescence (IF) (Figure 5-4). HDS is observed to bring about a red shift, suggesting 
hydrogen bonding and increase in polarity. HP brought about a slight blue shift, 
suggesting that the Trp residues are being exposed to a non-polar environment. Similar 
changes in polarity were seen with other BPs confirming the change in LYZ structure, as 
demonstrated by CD data. 
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Figure 5-4 : Representative fluorescence intensity profiles of HDS and HP on 0.1 mg/ml LYZ in phosphate 
buffer (pH 7) with 20 and 40 times mass excess. 
 
5.4.3.3 Effect of BPs on hgH structure 
 
The effect of BPs on the secondary structure of hgH was studied at 25 times mass excess 
(Figure 5-5). In contrast to LYZ, BPs were not observed to bring about major changes 
except for CS, which is known to have interference in the CD signal below 200 nm. 
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Figure 5-5 : Effect of BPs on 0.05 mg/ml hgH in bicarbonate buffer (pH 8) with 25 times mass excess by 
circular dichroism 
 
5.4.4 Isothermal Titration Calorimetry 
 
Thermodynamic analysis of protein-BP interactions were carried out using isothermal 
titration calorimetry (Table 5-1). Upon interaction, the change in enthalpy relates to the 
heat released or absorbed, whereas the change in entropy reflects the change in 
conformation as BP and protein combine to form a BP-protein complex. 
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Table 5-1: Thermodynamics of BP-LYZ interactions. ∆G and ∆S were calculated using ∆G = ∆H - T∆S. 
 
 
Enthalpy values calculated from ITC in macromolecular systems typically result from the 
formation and breakage of many different types of interactions. The individual 
Temp. 
(°C) 
BP Ka(10^6) 
(1/M) 
n # LYZ 
bound  
to one BP 
∆H 
(kJ/mol) 
∆S*T 
(kJ/mol) 
∆G 
(kJ/mol) 
4 LDS 3.8 ± 0.2 0.13 ~ 7 -499 ± 12 -465 -35 
8 LDS 3.2 ± 0.4 0.13 ~ 7 -423 ± 17 -389 -35 
24 LDS 2.1 ± 0.5 0.12 ~ 8 -488 ± 32 -452 -36 
37 LDS 16.7 ± 0.6 0.11 ~ 9 -365 ± 21 -322 -43 
4 CS 7.3 ± 0.1 0.03 ~ 30 -1159 ± 13 -1122 -35 
8 CS 7.8 ± 0.2 0.03 ~ 31 -1057 ± 21 -1020 -37 
24 CS 23.5 ± 0.2 0.04 ~ 29 -1052 ± 27 -1010 -42 
37 CS 53.3 ± 4.5 0.03 ~ 36 -1143 ± 38 -1097 -46 
4 HP 3.5 ± 0.2 0.09 ~ 12 -483 ± 29 -448 -35 
8 HP 2.1 ± 0.4 0.08 ~ 12 -474 ± 21 -440 -34 
24 HP 5.2 ± 0.6 0.09 ~ 11 -466 ± 37 -427  -38 
37 HP 3.2 ± 0.9 0.94 ~ 1 -41 ± 7 -2  -39 
145 
 
contributions may produce positive or negative enthalpy changes, thus severely 
complicating any attempt at further analysis of those values. The interactions were 
primarily found to be driven by enthalpy. Due to the strong electrostatic nature of 
interactions, the enthalpic changes were found to be large and negative. This is could be 
attributed to the electrostatic interactions involved in the binding. Larger polyions have 
been shown to have larger enthalpy [14, 16], possibly due to larger number of negative 
charges possessed by these ligands, which provide multiple binding sites through 
extended electrostatic interactions with the positive charges on the protein molecules. As 
expected, CS, which has a larger amount of charge and size, was found to be more 
exothermic, when compared to HP and LDS. Similar trend was reported for polyions 
interacting with growth hormones and parathyroid hormone [14, 34]. Enthalpic 
contributions were significantly less negative on a mole of charge basis. These adjusted 
enthalpies were similar for all ligands, consistent with major electrostatic contributions 
(Figure 5-6). This is contrasted, however, by the negative entropy values. The loss of 
entropy was expected, as the protein-BP complex would have lower degrees of freedom 
as they form a complex and due to the strong biding, as reflected by change in enthalpy. 
∆S values were also found to be similar across the BPs and became less favorable as the 
size of BP increased. Dependence of enthalpy on temperature is related to hydrophobic 
interactions or solvation level. A decrease in ∆H at higher temperature indicates that 
hydrophobic bonds are formed and vice-versa (Figure 5-6).    
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Figure 5-6 : Thermodynamics of BP-LYZ analyzed by ITC. The graphs represent the values of ∆G, ∆H, 
and -T*∆S. 
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Figure 5-7 : Enthalpy Vs temperature plotted for CS-LYZ, HP-LYZ, and LDS-LYZ binding interactions. 
 
The ∆G for the interactions were found to be negative for the BP's analyzed, indicating 
that the interactions are spontaneous and thermodynamically favored over the conditions 
investigated. The calculated Gibbs free energy were found to increase modestly with 
temperature, and were found to be similar to ones reported in the literature [14, 34]. 
Moderate to strong binding constants were observed for all interactions with Ka values in 
the micro-molar range  
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5.4.5 Differential Scanning Calorimetry 
 
Biochemical reactions tend to have smaller heat effects associated with them, when 
compared to chemical reactions. DSC has been widely used to investigate formulation 
stability by investigating thermal stability of liquid pharmaceuticals [35]. DSC 
experiments typically provide ∆Cp (change in heat capacity), ∆H (change in enthalpy), 
and Tm (midpoint of thermal transition) for a reversible transition. 
 
The effect of temperature on protein stability is complex, and proteins are known to 
aggregate and precipitate with an increase in temperature. The solvation process being 
spontaneous has negative free energy associated with it, leading to a highly negative ∆H 
(∆G = ∆H - T∆S). Water molecules are known to orient around hydrophobic groups of 
protein in solution, and the change in entropy is negative. Thus, the ∆H of the 
aggregation/precipitation process will be positive and the Arrhenius equation will 
predicts that the process will accelerate with temperature [22]. 
 
Thermal unfolding of proteins is known to be irreversible primarily due to 
aggregation/precipitation, thus there is no equilibrium to calculate accurate 
thermodynamic equilibrium parameters. Thus, DSC thermal profiles were analyzed to 
obtain apparent midpoint of transition (Tm) and calorimetric enthalpy (∆Hcal). Higher 
values of Tm and Hcal are indicative of a higher stability. Native protein is considered 
enthalpically more stable than the denatured form, due to packing and hydrogen bonds 
contributions to enthalpy. 
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The effect of the BPs on thermal stability of protein was analyzed by DSC thermograms 
of proteins (1 mg/ml) in the presence of 40X (mass) of BP. 
 
5.4.5.1 Effect of BP on LYZ Tm 
 
Figure 5-8 : Effect of BPs on the thermal stability of 1 mg/ ml LYZ in 10 mM phosphate buffer at pH 7( at 
40 fold weigh excess of BPs). 
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In case LYZ, the Tm of 1 mg/ml protein in 10 mM phosphate buffer at pH 7 was ~ 74 °C 
(Figure 5-8). HDS, SO and HP were observed to reduce the apparent Tm of LYZ. The 
presence of an exothermic event before the Tm, indicates an aggregation/precipitation 
event prior to unfolding. LDS was found to bring about precipitation of LYZ from the 
solution, making the DSC prolife not useful for analysis. PA was observed to marginally 
improve the thermal stability of LYZ in solution. 
 
The difference in the baseline before and after the Tm, gives an idea about the change in 
heat capacity (∆Cp) brought about by the transition. ∆Cp are known to be associated with 
the reversibility of the transition, higher ∆Cp tend to reduce the reversibility of the 
transition. From the DSC profiles (Figure 5-8), the highest ∆Cp was observed in the case 
of LYZ, whereas the BPs observed to reduce the ∆Cp.  
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Table 5-2 : Analysis of LYZ DSC profiles using NanoAnalyze software
8
 
 
Sample Aw Tm (°C) ∆H (kJ/mole) 
LYZ Control 0.249 ± 0.001 73.64 ± 0.02 507.7 ± 4.69 
40X HDS 0.201 ± 0.001 64.21 ± 0.015 941.9 ± 9.53 
40X HP 0.521 ± 0.015 70.05 ± 0.040 584.2 ± 10.03 
40X PA 0.576 ± 0.009 74.86 ± 0.027 560.9 ± 5.66 
40X SO 0.640 ± .007 71.20 ± .020 500.7 ± 3.651 
40X LDS NA NA NA 
40X CS NA NA NA 
 
 
In the presence of HDS, ∆Hcal of the transition increased by ~ 440 kJ/mol, suggesting that 
the HDS and LYZ interacted strongly in solution. HP and PA were also observed to 
increase ∆Hcal by ~ 60-70 kJ/mol, but presence of SO did not affect the ∆Hcal. No analysis 
was feasible for the data in the presence of CS and LDS, due to precipitation/ aggregation 
issues. 
  
                                                 
8
 The raw DSC data was fit to the two-state scaled model, with appropriate controls. The quality of the fit 
was ascertained by running a statistical analysis with a 1000 trials where the parameters were varied around 
the fit (95 % confidence interval). Samples were run in triplicate and the data is reported as mean ± error in 
fit. 
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5.4.5.2 Effect of BP on HgH Tm 
 
Figure 5-9 : Effect of BPs on the thermal stability of 1 mg/ ml 4mM bi-carbonate buffer at pH 8 ( at 40 fold 
weigh excess of BPs). 
 
1 mg/ml of hgH in 4mM bicarbonate buffer at pH 8 was observed to have an apparent 
Tm of ~ 85 °C (Figure 5-9). All BPs were noted to reduce this temperature, suggesting 
that they reduced the thermal stability of hgH in solution. Surprisingly, the apparent Tm in 
the presence of BPs was very similar (~ 76 - 78 °C). PA profile was not reported due to 
aggregation/precipitation events. From the baselines before and after the transition, ∆Cp 
was observed to be higher for hgH control, CS and LDS, suggesting that the transitions 
had a higher irreversibility, compared to other transition profiles. The hgH DSC data was 
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fit using the two-state scaled model in NanoAnalyze software (Table 5-3). The ∆Hcal was 
found to be increase from ~ 550 kJ/mol in the presence of BPs. The largest increase was 
seen in the case of LDS, where the ∆Hcal was reported to be ~ 755 kJ/mol. Similarly large 
increases in ∆Hcal for was observed HP and SO, suggesting that LDS, SO and HP 
interacted strongly to the hgH in solution. Analysis of PA profile was not feasible due to 
aggregation/precipitation events. 
 
Table 5-3: Analysis of hgH DSC profiles using NanoAnalyze software
9
 
 
Sample Aw Tm (°C) ∆H (kJ/mole) 
hgH Control 0.378 ± 0.008 85.36 ± 0.04 550.1 ± 7.45 
40X HDS 0.285 ± 0.006 77.99 ± 0.028 702.8 ± 9.66 
40X LDS 0.238 ± 0.015 77.95 ± 0.032 755.4 ± 11.87 
40X HP 0.229 ± 0.005 77.86 ± 0.025 728.1 ± 9.85 
40XCS  0.242 ± 0.001 77.40 ± 0.023 686.7 ± 9.69 
40X SO 0.522 ± 0.006 78.90 ± 0.029 744.4 ± 10.78 
40X PA NA NA NA 
 
 
                                                 
9
 The raw DSC data was fit to the two-state scaled model, with appropriate controls. The quality of the fit 
was ascertained by running a statistical analysis with a 1000 trials where the parameters were varied around 
the fit (95 % confidence interval). Samples were run in triplicate and the data is reported as mean ± error in 
fit. 
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Overall, the addition of BPs to LYZ and hgH resulted in decrease of the apparent Tm in 
some cases. Inspite of the destabilization of the protein, it does not necessarily suggest 
that the presence of BPs leads to a poor formulation. Protein-BP interactions could 
potentially inhibit protein-protein interactions, which have been shown to cause 
aggregation and protein degradation. In addition, these interactions might protect the 
protein formulation during processing, manufacturing, handling and enhance therapeutic 
effect by acting as a co-factor [11, 36, 37].   
 
5.5 Conclusions 
 
Growth factors are known to be thermally labile, to the extent that they are known to 
undergo structural transitions below 40 °C possibly due to being intrinsically disordered 
[12, 37, 38]. While the proteins undergo a change in structure around 37 °C, a significant 
portion of the native structure is retained. These inductions of structural changes in the 
proteins upon binding to the polysaccharides in the ECM may have biological 
significance. Since a number of these proteins (e.g. FgF family [39]) are presented in this 
bound form, it is crucial to understand the interactions between the polyions and proteins 
in the normal and diseased state. The interactions between polysaccharides and growth 
factors in the ECM are commonly explained by the role of the polyionic proteoglycans on 
the surface of cells, to present the growth factors to their protein kinase receptors. Other 
roles for the interactions include chaperon like behavior, intracellular transportation and 
localization, stabilizing effect, etc [8, 12, 39, 40].  
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Our data suggests that the LYZ structure was altered by BPs in solution, especially larger 
BPs like HDS and SO, which could lock LYZ into a particular conformation and bring 
about steric hindrance. This change was observed in CD and IF data. In contrast, for hgH, 
not a large change in secondary structure was seen. . In addition, it was not possible to 
carry out structural elucidation of FgF-20 and VEGF with BPs due to the presence of Arg 
and polysorbote 20, respectively, to stabilize and solubilize proteins in solution. Analysis 
of hgH via IF was not feasible due to the poor fluorescence characteristics of hgH  
 
The BPs used in the study demonstrate enthalpically driven binding to LYZ with 
significant affinity. In many cases, macromolecules that bind charged compounds are 
known to be entropically driven, with small ∆H values. However, numerous examples of 
electrostatic interactions between macromolecules and ions are reported that are driven 
enthalpically [41-43]. The degree of the entropy change may be related to number of 
binding sites on macromolecule or ligand. Protein binding to polyions has also been 
reported to be enthalpically driven in many cases [12-14, 34]. Multiple LYZ molecules 
were demonstrated to bind to the BPs, with CS having the largest number of bound LYZ.    
 
The DSC data indicates that the addition of BPs to the protein resulted in decrease of the 
Tm in most cases. Inspite of the destabilization of the protein in solution, this does not 
necessarily suggest that the BP leads to poor formulations [12, 14]. It is important taht 
DSC data is dependent on the concentration and most of the pharmaceutical protein 
solutions are at high concentration. Protein-BP interactions could potentially inhibit 
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protein-protein interactions, which have been shown to cause aggregation and protein 
degradation. In addition, protein-BP interactions might protect the protein formulation 
during processing, manufacturing, handling and enhance therapeutic effect by acting as a 
co-factor [11, 36, 37]. Thus, BP could be explored excipients for formulating proteins, 
which are, known to self-associate and aggregate [37].  
 
The existence of a vast polyanionic network at the cellular level and reports in the 
literature suggest that extensive polyanion-protein interactions mediate a whole range of 
cellular processes [37, 40, 44]. The effect of BPs/polyanions on the structure of the 
growth factors raises the question about the growth factors around physiological 
conditions, in the presence of numerous polyions. The influence of concentrated solution 
of polysaccharides on protein stability is hypothesized to be drive by chemical 
interactions and hard-core repulsion [45]. As hard-core repulsions would involve only the 
arrangement of molecules, they would be expected to affect the entropic component of 
protein stability. A vast majority of protein stability studies reported in the literature have 
been performed using dilute buffer with low concentration of proteins (usually  1 
gm/ml). This differs to a great extent form environment encountered by proteins within 
cells, where the total macromolecular concentration amounts to several hundred gms/ml 
[46]. The crowding leads to non-specific forces, which promote reduction in total volume 
and formation of compact macromolecular complexes. Such crowding behavior was 
found to be responsible for the stabilizing effect of dextran on cytochrome c [47]. At the 
macromolecular concentration needed to bring about macromolecular crowding, a 
substantial increase in volume occupancy was observed with a reduction in water 
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concentration. Excluded volume model was found to explain this stabilizing effect of 
dextran at very high concentration [47]. There are still a lot to understand about the effect 
of macromolecular crowding on the interactions between polyanions and proteins in vivo, 
especially since a majority of the work in the field fails to account for this in their work. 
This has important implications for understanding biologically active proteins that have 
little or no structure in dilute solutions [48]. 
 
Whatever the implications of polyion concentration on biological stability of proteins, the 
potential exists for the use of suitably selected BP like polyanion to formulate therapeutic 
formulations of proteins, which tend to aggregate and self associate.  
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CHAPTER 6 Significance and Future Directions 
 
6.1 Significance 
 
The data described in this thesis indicates that the biometric approach could be used to 
successfully ASE proteins at very high efficiency and bring about release of active 
proteins over 60 days [1]. The biomimetic approach provides significant advantages over 
traditional encapsulation paradigms. For example, a) outstanding protein stability during 
encapsulation is observed owing to the absence of organic solvents, high shear, and other 
protein-denaturing processes; b) high protein loading (~ 4-7 % w/w) and efficiency 
(>90%) of encapsulation is achievable suitable for pharmaceutical protein controlled 
release by simple mixing of blank BP-PLGA microspheres with aqueous protein solution 
and heating; c) appropriately chosen BPs can act as potential co-factors for the protein 
being delivered, greatly enhancing therapeutic effect, and reducing protein dosage and 
costs; d) there is a potential for controlled release of active protein over 4-8 weeks; and e) 
a potential to sterilize ASE microsphere formulations by gamma irradiation, allowing for 
bulk manufacturing for multiple growth factors or other compatible proteins [2]. 
 
This work builds upon the previous work done in our group [3, 4], by expanding our self-
encapsulation paradigm for therapeutic proteins at low protein concentrations making it 
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possible to quickly develop and evaluate controlled release formulations. In the past, 4-10 
% w/w LYZ loading was reported via passive self-encapsulation using 250 mg/ml LYZ 
[5], but the prohibitive cost of this approach is not very feasible for encapsulation of 
recombinant therapeutic proteins. In contrast, ASE of pharmaceutical proteins using the 
biomimetic approach described here could be brought about by simply mixing 
microsphere formulations with low concentration protein solutions (<10 mg/ml), to 
reduce losses of expensive recombinant proteins during formulation. The ease of 
developing and evaluating new pharmaceuticals using this approach along with the 
potential to bring about sterilization at the end [2], could potentiality overcome some of 
the issues seen with scale-up [6], and open up avenues for commercialization of new 
PLGA based microsphere delivery systems. The ability of BPs to act as co-factors and 
enhance the biological effect of the protein could potentially reduce dosage and cut costs [7-
9]. 
 
The absorption data also supports the use of this approach as a new facile method to 
microencapsulate off-the-shelf therapeutic proteins with SM polymer excipients, 
suggesting that suitably selected BPs could be incorporated in materials of any shape and 
form, e.g., eluting stents, sutures, biodegradable implants, etc., for protein delivery. 
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6.2 Issues and Future Directions 
 
One of the major issues with the development of BP-PLGA ASE microspheres was 
related to the change in properties of the system brought about by use of new batches of 
PLGA and BP. This issue is common across development done at lab scale and leads to 
inconstancies among the data produced. This was seen in loading and release data 
reported in chapter 4 (Figure 4-14). 
 
Another concern was the possibility of BP leeching out of the BP-PLGA microsphere 
during the loading and release process. This was more plausible in the case of BP with a 
low Mw, e.g. LDS and HP. Leeching was seen in some cases with LDS, especially with 
the attempts to ASE anti-VEGF Fab. Due diligence is also required to ensure that the 
protein is stable during the loading and pore closing, due to prolonged exposure to a high 
temperature (for pore closure).  
 
A better understanding of the pore closing phenomenon would allow us to improve BP-
PLGA microsphere's pore closing properties. The addition of excipients and BPs would 
also affect PLGA pore closure, and needs to be studied in detail. Some of the BPs are 
hydrophilic and hygroscopic, absorbing high amounts of water and potentially acting as 
plasticizers. Understanding the thermodynamics and kinetics of BP-protein interactions is 
crucial for developing LAR products. The role of ka and Mw of BP on protein binding and 
retention inside the microsphere needs to be better understood to develop better 
formulations with desired release kinetics. One way to gain better insight would be to 
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determine the interactions and concentrations of BPs and proteins inside the micro-pores 
of the PLGA microspheres. Efforts should also be directed towards investigating the 
effect of BP and its distribution on the pore structure of the PLGA polymer. For example, 
we need to understand how to control the co-distribution of BPs and encapsulated 
protein, which would be important for developing formulations with optimal release 
kinetics and minimal protein residue in the polymer matrix.        
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